6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor lig

专利摘要:

公开号:AU2008357946A1
申请号:U2008357946
申请日:2008-06-20
公开日:2009-12-23
发明作者:Gianfranco Caselli；Antonio Giordani；Marco Lanza；Francesco Makovec；Stefano Mandelli；Lucio Claudio Rovati；Simona Zanzola
申请人:Rottapharm SpA；
IPC主号:C07D213-00

专利说明:
WO 2009/152868 PCT/EP2008/057908 1 6-1 H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES/MAO INHIBITORS FOR TREATING DEPRESSION The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quina zoline and quinolines derivatives acting as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands, to a process for their preparation, and to the use of such compounds, their pharmaceutical acceptable salts and solvates, and corresponding pharma ceutical compositions, for the pharmacological treatment of depression and related disor ders, Parkinson disease, drug abuse, and morphine tolerance and dependence. Background Depression is a common and harmful mood disorder that affects emotion, cognition, and behaviour; rather than a clearly defined disease, depression involves a wide spectrum of disorders ranging from the feeling of unhappiness to more severe incapacitating disorders such as Clinical depression (also called major-depressive disorder or unipolar depression), Dysthymic disorder, Bipolar disorder, Atypical depression, Psychotic depression, Postpar tum depression and Seasonal affective disorder (A. Doris et al. Depressive illness, Lancet, 1999, 354, 9187, 1369). According to the World Health Organization (WHO), depression is characterized by depressed mood, loss of interest or pleasure, feelings of guiltiness or low-self-esteem, disturbances in sleep and/or appetite, poor concentration. Major depres sive disorder, also known as major depression, is the most common type of depression with about 10-25% lifetime risk in the industrialized countries population. It is characterized by a combination of symptoms and disabling conditions that seriously interfere with work and family life, sleeping and eating habits, and with the general health of the patient. Dyst hymic disorder, also called dysthymia, is characterized by long-term less severe symptoms that may not disable a person but can prevent a person of feeling well thus impacting the social life. Bipolar disorder, also called manic-depressive illness, is characterized with cy cling mood changes from extreme highs (e.g., mania) to extreme lows (e.g., depression). Atypical Depression is a subtype of dysthymia and major depression characterized by mood reactivity and vegetative symptoms like over-eating and over-sleeping. Psychotic depression, occurs when a severe depressive illness is accompanied by some form of psy chosis, hallucinations, and delusions. Postpartum depression, which affects 10-15% of WO 2009/152868 PCT/EP2008/057908 2 women, is diagnosed if a major depressive episode occurs within one month after the childbirth, the disease has similar symptoms as clinical depression. Seasonal affective dis order, is characterized by the onset of a depressive illness during the winter months. De pressive and anxiety symptoms often overlap. Anxiety disorders comprise post-traumatic stress disorder, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder. Panic disorder is classified as an anxiety disorder since anxiety is the predominant symp tom, panic attacks are discrete episodes consequence of a panic disorder. The development of severe phobic symptoms matches the escalation in frequency and intensity of panic at tacks, leading to a severe and disabling disorder which impacts the patient professional, social and familial life. Depression may be a primary condition or can co-exists with other serious medical illnesses such as heart disease, stroke, cancer, diabetes and Parkinson's disease. Clinical studies have shown that people who have depression in addition to an other serious medical illness tend to have more severe symptoms of both depression and the medical illness, more difficulty adapting to their medical condition, and more medical costs than those without co-existing depression. Research has provided evidences that treating the depression can also help at improving the outcome of treating the co-occurring illness. Alcohol, tobacco and drug abuse may also co-occur with depression. In fact, statis tical research indicated that the co-existence of mood disorders is pervasive among the people involved in alcohol, tobacco and drug abuse. Depressive disorders are extremely common, affecting about 120 million people worldwide each year. According to WHO de pression is a leading cause of disability and it is the fourth most important contributor to the global burden of disease. Morbidity and mortality in depressed patients are higher than in normal subjects. According to the National Institute of Mental Health (NIMH) recent studies highlighted how persons with major depression were four times as likely to suffer of a heart attack as not depressed controls. According to NIMH direct and indirect social costs of depression amounted for the year 1990 to about 30 billion USD, being indirect costs represented by decreased worker productivity and disruption of personal, profes sional and family relationships. An analogue evaluation in Europe for year 2004 high lighted a social cost of 118 billion Euro, pointing out depression as the most costly brain disorder in Europe. According to the monoamine hypothesis, depression is caused by an imbalance of these WO 2009/152868 PCT/EP2008/057908 3 neurotransmitters in the brain. One pharmacological strategy aimed at overcoming this im balance consists of inhibiting the enzyme Monoamine Oxidase (MAO; EC 1.4.3.4). The monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE) and dopamine are widely distributed within the brain and are involved in the regulation of mood, cognition, sleep, anxiety and social behavior. Dysfunctions in mechanisms controlling these neuro transmitters are often associated with most major psychiatric disorders and drugs targeting monoamine neurotransmitters have been and are widely investigated for the treatment of depression. MAO is a FAD dependent enzyme (flavoprotein) mainly located in outer mito chondrial membranes of neurons and glial cells as well as in other cells of the periphery (i.e.: epatocytes), where it catalyzes the oxidative deamination of neurotransmitter, xenobi otic and endogenous amines. The antidepressant approach for MAO inhibitors is based on the fact that by inhibiting the enzyme activity, deactivation of these endogenous neuro transmitters is prevented thus increasing both their synaptic concentration and duration of action. There are two isoforms of MAO: MAO-A which preferentially deaminates sero tonin, norepinephrine and epinephrine, but also amines present in foods like tyramine, and MAO-B which preferentially deaminates dopamines, phenylethylamines and benzylamines (B.H. Moussa, British J. Pharmacolgy, 2006, 147, S287-296). The first generation of MAO inhibitors not selectively and irreversibly blocked both MAO isoforms this led to side effects such as hypertensive crisis (also called "chese syndrome") especially due to MAO A inhibition, that blocking tyramine metabolism trigger a cascade in which excessive amounts of norepinephrine can lead to a hypertensive crisis. Second generation MAO-A reversible inhibitors such as moclobemide and brofaromin displayed in clinical trials po tent antidepressant activity but a negligible propensity to induce after ingestion of tyramine, hypertensive crisis at the therapeutic dosage (Bonnet U., CNS Drug review, 2003, 9, 1, 97-140). This because reversibility allows competition and thus ingested tyramine is able to displace the inhibitor from the enzyme. MAO-B selective reversible in hibitors do not give rise to hypertensive crisis. Recent studies provide evidence that also anxiety disorders may be linked to malfunction in serotonine neurotransmission and unbal ances in catecholamine metabolism. Efficacy of MAO inhibitors in the treatment of anxi ety disorders has been demonstrated by several clinical trials and case reports (J. Clin. Psy chiatry, 2006, 67, S12:20-26). Inhibitors of MAO-B prolong the activity of both endoge nously and exogenously derived dopamine, making them an option either as monotherapy WO 2009/152868 PCT/EP2008/057908 4 in early Parkinson's disease (PD) or as add-on therapy in patients treated with levodopa. Efficacy of the MAO-B approach for the PD treatment was clinically proved by trials in volving the two US approved MAO-B inhibitors Rasagiline and Selegiline as well as using Safinamide, at the present in phase III. All these drugs provided symptomatic relief when used as monotherapy or as adjunctive therapy, even displaying potential as disease modifying agents. Imidazoline receptors, a family of non-adrenergic receptors, first identified by Bousquet in 1984, are widely distributed both centrally and peripherally. Three main subclasses of imi dazoline binding sites (IBS) have been identified: 1 1 -IBS, which preferentially binds clo nidine, is located on the membrane of neurones and is involved in the central blood pres sure regulation, 1 2 -IBS, which preferentially binds idazoxan, is located principally in the outer membrane of mitochondria, and 1 3 -IBS that has been identified in the pancreas. Pro tein isolation studies have shown that MAO-A and MAO-B are both 12 binding proteins. Further pharmacological studies demonstrated how agonists at 1 2 -IBS are able to inhibit MAO activity thus providing an alternate approach to MAO inhibitors for controlling the activity of both MAO-A and MAO-B. It was shown in several animal models how 1 2 -IBS ligands are able to modulate central monoamine levels, as well as it has been recently shown how alterations in I 2 -IBS density can be highlighted in depressed patients. Agman tine is an endogenous amine, formed by arginine decarboxylation, which has been pro posed as a neurotransmitter in the CNS, Recently for Agmantine and other selective 1 2 -IBS agonists such as 2-BFI (2-benzofuranylimidazoline) and norharman (p-carboline) antide pressant properties in several animal models have been reported, thus confirming in vivo that 1 2 -imidazoline receptor is a new pharmacological target for the treatment of depression and related disorders (MP Zeidan, Eur. J. Pharmacology, 2007, 565, 1-3, 125-31). Narcotic and alcohol withdrawal is often accompanied by atypical depression which give rise to resumption of alcohol or narcotics, accordingly antidepressant treatment including treatment with MAO inhibitors can generally be considered as a phannacological approach to treat narcotic and alcohol abuse. However in some cases MAO inhibitors have been proven by preclinical or clinical trials even superior than other anti-depressive drugs for several reasons.
WO 2009/152868 PCT/EP2008/057908 5 Nicotine induces tollerance and addiction by acting on the central dopaminergic pathways, thus only 50% reduction in nicotine consumptions may trigger withdrawal symptoms such as anxiety, depressive symptoms, cognitive disorders, sleep disorders. The use of MAO in hibitors as a new pharmacotherapy for the treatment of smoking dependence is based upon both the compensation effect of these drugs on the dopaminergic pathway and to the anti depressive effects that should avoid remission episodes (T.P. George et al., Clin. Pharma col Ther., 2008, 83, 4, 619-21). Cocaine abuse is a serious health problem in many areas of the world, up to date there are no approved pharmacological treatments to overcome cocaine dependence. Preclinical studies suggest that cocaine dependence may be due to dopamine transporter inhibition ex erted by cocaine, which give rise to a dopamine reinforced effect. MAO inhibitors and par ticularly MAO-B inhibitors, as proved by preliminary trials with the MAO-B inhibitor se legiline, increasing the monoamine levels can help in overcoming cocaine dependence counteracting the dopamine level drop due to the drug withdrawal (E.J. Houtsmeller, Psy chopharmacology, Berl., 2004, 172, 1, 31-40). Preclinical models highlighted how 1 2 -IBS ligands enhances analgesic action of morphine and inhibits tollerance and dependence to opioids (A. Mirales et al., Eur. J. Pharmacology, 2005, 22, 518, 2-3, 234-242). Agmantine and 2-BFI along with other 1 2 -IBS agonists have been shown to potentiate opioid induced analgesia and to attenuate the development of tol erance and dependence, while 1 2 -IBS antagonist such as idazoxan completely reversed these effects. Interestingly, the same effects of potentiation of morphine analgesia and pre vention of tollerance and dependence was observed in animal models also with MAO in hibitors (A Wasik et al., J. Physiol. Pharmacol., 2007, 58, 2, 235-52; K Grasing et al., Be hav Pharmacol., 2005, 16,1,1-13), and confirmed clinically for Moclobemide, a reversible MAO-A inhibitor (G. Vaiva, Prog. Neuropsychopharmacol Biol. Psychiatry, 2002, 26, 3, 609-11). Description of the Invention In our previous patent application W02008/014822 we described 2-aryl- and 2-hetroaryl- WO 2009/152868 PCT/EP2008/057908 6 6-(1H-imidazo-1-yl)-quinazoline and quinoline derivatives for the treatment of pain and in flammatory disorders. More recently we have discovered that 2-aryl- and 2-hetroaryl-6 (1H-imidazo-1-yl)-quinazoline and quinoline derivatives of formula (I) are surprisingly endowed with outstanding MAO inhibitory properties and are potent 1 2 -IBS agonists. Ac cordingly, the present invention is directed to the use of compounds of formula (1), their pharmaceutically acceptable salts and/or solvates, and corresponding pharmaceutical com positions, for the pharmacological treatment of Depression including Major depressive disorder, Dysthymic disorder, Type II bipolar disorder, manic depression, Anxiety disor ders including post-traumatic stress disorder, panic disorder. According to the rational reported in the background, this invention is further directed to the use of compounds of formula (I), their pharmaceutically acceptable salts and/or sol vates, and corresponding pharmaceutical compositions, for the pharmacological treatment of Parkinson's disease. In another embodiment this invention is directed to the use of com pounds of formula (I), their pharmaceutically acceptable salts and/or solvates, and pharma ceutical compositions thereof, for the pharmacological treatment of the withdrawal symp toms and to avoid remission episodes for alcohol, tobacco and narcotics abuse including Cocaine abuse. In another embodiment this invention is directed to the use of compounds of formula (I), their pharmaceutically acceptable salts and/or solvates, and corresponding pharmaceutical compositions, where compounds of formula (I) are used alone or in combi nation with morphine or other opioid drugs for potentiation of the opioid pharmacological action and/or for the dosage reduction of the opioid drug. In another embodiment this in vention is directed to the use of compounds of formula (I), their pharmaceutically accept able salts and/or solvates, and pharmaceutical compositions thereof, for the treatment of tolerance and dependence due to opioid drugs use. Compounds of Formula (I): R1 1 RW wherein: - X is independently selected from -CH group or a nitrogen atom (-N); WO 2009/152868 PCT/EP2008/057908 7 - W is independently selected from an aryl group, an heteroaryl group, or an heteroaryl group of formula II: Z Q Y Heteroaryl group of formula II - when W is an aryl group, it is intended an unsubstituted or substituted phenyl, with one or more substituents independently selected from halogen (-F, -Cl, -Br), trifluoromethyl (
CF
3 ), alkyl (-R2), hydroxyl (-OH), alkoxy (-OR2), trifluoromethoxy (-OCF 3 ), cyano (-CN), carboxamido (-CONHR 3 or -NHCOR 3 or -CONR 2
R
3 or -NR 2
COR
3 ), carbonyl (-CO-R 3 ), alkylthio or thiol (-SR 3 ), sulfinyl (-SOR 3 ) and sulfonyl (-S0 2
R
3 ) being R 2 and R3 as de fined below; - when W is an heteroaryl group it is independently selected between the following penta or hexa-atomic heterocycles: 2-faryl, 3-furyl, 2-thienyl, 3-thienyl, pyrrole-2-yl, pyrrole-3 yl, pyridine-4-yl, pyridine-3-yl, pyrimidin-4-yl. The heterocyclic ring can be substituted with one or two substituents independently selected from: R 1 , alkoxy (-OR 2 ) or hydroxy ( OH), being R, and R2 as defined below; - when W is an heteroaryl group of formula (II), it is a benzocondensed -5 or -6 membered heterocycle, wherein: - Z and Y are independently selected from: an oxygen atom (-0-), a sulphur atom (-S-), or the groups: -CHR 3 -, -CR 3 =, -NH-, -N=; - Q is independently selected from the groups: -CHR 3 -, - CH=, -CR 3 =, -CHR 3
-CH
2 -; provided that the combination of Y, Z, Q groups give rise to: 1,3-benzodioxole, benzofu ran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihy droindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [1,4] benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan); - R, is independently selected from hydrogen (-H), C-C 4 alkyl, hydroxymethyl (-CH 2 OH), aminomethyl (-CH 2
NH
2 ), alkylaminomethyl [CH 2
NH(R
2 )], or di-alkylaminomethyl
[CH
2
N(R
2
)
2 ] trifluoromethyl (-CF 3 ). The C-C 4 alkyl group is a linear or branched satu rated or unsaturated C-C 4 hydrocarbon chain. Provided that in compounds of formula (I) not more than two R, groups substituting the imidazole ring, are simultaneously C-C 4 al kyl or trifluoromethyl (-CF 3 ) and only one R 1 group is hydroxymethyl (-CH 2 OH), ami- WO 2009/152868 PCT/EP2008/057908 8 nomethyl (-CH 2
NH
2 ), alkylaminomethyl [CH 2
NH(R
2 )], or di-alkylaminomethyl
[CH
2
N(R
2
)
2 ]; - R2 is a C-C 6 alkyl chain. Herein the C 1
-C
6 alkyl chain is intended as above defined for
C
1
-C
4 chain but optionally substituted with an aryl, aryl being herein as defined above; - R3 is independently selected from hydrogen, C-C 4 alkyl as defined above for R1. Compounds of formula (I) as defined above have tautomers, the scope of the present in vention includes all the possible tautomers of compounds of formula (I). Compounds of formula (I) as defined above, when W is an aryl or an heteroaryl of formula (I) are encompassed within the compounds of formula (I) of our previous application W02008/014822, however some of them are novel compounds, not previously described in the examples of our patent application W02008/014822. In a further embodiment this invention is directed to these novel compounds, their pharma ceutically acceptable salts and solvates, the corresponding pharmaceutical compositions, and their use for the pharmacological treatment of those diseases as above detailed for compounds of formula (I). These novel compounds are: [6-(2-methyl-1 H-imidazol- 1 -yl)-2-phenyl]quinazoline. [6-(2-methyl-l H-imidazol- 1 -yl)-2-(4-methoxyphenyl)]quinazoline [6-(4-methyl- 1 H-imidazol- 1 -yl)-2-phenyl]quinazoline. [6-(5-methyl- I H-imidazol- 1 -yl)-2-phenyl]quinazoline. [6-(4-methyl- I H-imidazol- 1 -yl)-2-(4-methoxyphenyl)]quinazoline. [6-(4-methyl- 1 H-imidazol- 1 -yl)-2-(3 -methoxyphenyl)]quinazoline. [6-(4-methyl-I H-imidazol- I -yl)-2-(2-methoxyphenyl)]quinazoline. [6-(4-1H-imidazol-1-yl)-2-(1,3-benzodioxol-5-yl)]quinazoline. [6-(4-methyl- I H-imidazol- I -yl) -2-(4-fluorophenyl)]quinazoline. [6-(4-methyl- I H-imidazol- 1 -yl)-2-(4-metanesulfonylphenyl)]quinazoline. [6-(1H-imidazol-1-yl)-2-(4-methoxyphenyl)]quinoline. [6-(l H-imidazol- 1 -yl)-2-(2-methoxyphenyl)]quinoline.
WO 2009/152868 PCT/EP2008/057908 9 [6-(1 H-imidazol- 1-yl)-2-(1,3-benzodioxol-5-yl)]quinoline. [6-(1H-imidazol- 1 -yl)-2-(4-fluorophenyl)]quinoline. [6-(1 H-imidazol- 1 -yl)-2-(4-dimethylaminophenyl)]quinoline [6-(1 H-imidazol- 1 -yl)-2-(4-trifluoromethoxyphenyl)]quinoline. [6-(1 H-imidazol-1 -yl)-2-(2-methyl-4-trifluoromethoxyphenyl)]quinoline. [6-(1 H-imidazol-I -yl)-2-(4-dimethylaminophenyl)]quinoline. [6-(1 H-imidazol-I -yl)-2-(4-methansulfonylphenyl)]quinoline. [6-(2-methyl- I H-imidazol- 1 -yl)-2-(4-methoxyphenyl)]quinoline. [6-(2-methyl- I H-imidazol- 1 -yl)-2-(2-methoxyphenyl)]quinoline. [6-(4-methyl- 1 H-imidazol-1 -yl)-2-phenyl)]quinoline. [6-(4-methyl- 1H-imidazol-1 -yl)-2-(4-methoxyphenyl)]quinoline. [6-(4-methyl- 1 H-imidazol- 1 -yl)-2-(4-fluorophenyl)]quinoline. [6-(4-methyl- I H-imidazol- 1 -yl)-2-(4-methylthiophenyl)]quinoline. Compounds of formula (I) as defined above, when W is an heteroaryl as above defined, are not encompassed within the compounds of formula (I) of our previous application W02008/014822. In a further embodiment this invention is directed to these novel compounds of formula (I) where W is a heteroaryl as above defined, their phannaceutically acceptable salts and sol vates, the corresponding pharmaceutical composition, and their use for the pharmacologi cal treatment of those diseases as detailed for compounds of formula (1). According to this invention the compounds of formula (I) may be used as the free base, as a pharmaceutically acceptable salt, or as a solvate or hydrate form. The salts of compounds of formula (I) are pharmaceutically acceptable addition salts with inorganic and organic ac ids. Representative not limiting examples of inorganic salts of compounds of formula (I) are: hydrochloride, hydrogensulphate, sulphate, hydrogenphosphate and phosphate. Corre sponding representative not limiting examples of organic salts are: methanesulfonate, maleate, succinate, fumarate, tartrate, malonate and oxalate. Methods for the preparation of compounds of formula (I) are widely described in our pre- WO 2009/152868 PCT/EP2008/057908 10 vious application W02008/014822, however especially for those compounds of formula (I) where the imidazolyl group is substituted (Ri is not hydrogen), very low yields and complex reaction mixtures are often obtained when the methods for the preparation of compounds of formula (I) reported in W02008/014822 are used. In another embodiment this invention provides new, more practical and valuable methods for preparing com pounds of formula (I), characterized by higher average yields and simpler procedures for the isolation and purification of the product. In another embodiment this invention provides pharmaceutical compositions for com pounds of formula (I) useful for the pharmacological treatment of those diseases as above detailed. Within the scope of the present invention the term pharmaceutical composition (drug product) refers to any oral or parenteral dosage form, suitable for the treatment of the above pathologies, that contains an effective amount of at least one of the active pharma ceutical ingredients (drug substances), compounds of formula (I), its salts or solvates thereof, and a pharmaceutically acceptable carrier, excipients or diluents as defined below, for oral or parenteral administration. Representative not limiting examples of compounds of formula (I) are listed in Table 1. Table 1: Name Structure MW Example [6-(lH-imidazol-1-yl)-2-phenyl- N ]quinazoline. N ':':272.31 1 [6-(2-methyl-IH-imidazol-1-yl)-2 phenyl)-]quinazoline. NN286.34 2 [6-(2-methyl-I H-imidazol- l-yl)-2-(4 methoxyphenyl)-Jquinazoline. N( N 316.37 3 0 WO 2009/152868 PCT/EP2008/057908 11 [6-(4-methyl-IH-imidazol-1-yl)-2- N p h en y liqu in azo lin e. N 2 . 4 SN _ N286.34 4 [6-(5-methyl-IH-imidazol-1-yl)-2- N phenyl)]quinazoline. N316.37N N N. 286.34 5 [6-(4-methyl- H-imidazol-1-yl)-2-(4 methoxyphenyl)]- quinazoline. N ' X N :
-
3 16 .3 7 6 [6-(4-methyl-1H-imidazol-1-yl)-2-(2- N methoxyphenyl)-]quinazolie. N N- N N. 316.37 7
A-
[6-(4-methyl-1H-imidazol-1-yl)-2-(3- N methoxyphenyl)-]quinazoline. N N; N. 316.37 8 [6-(4-methyl-1H-imidazol-1-yl)-2 (i,3-benzodioxol-5-yl)-]quinazoline. N N 330.35 9
I
[6-(4-methyl-IH-imidazol-1-yl)-2-(3- N fluorophenyl)-]quinazoline. NI N k F 304.33 10 [6-(4-methyl-1IH-imidazol-1I-yl)-2- N (4-methanesulfonylphenyl)]- quina- NNN zoline.N A- " 364.43 1 [6-(4-methyl- 1H-imidazol-1l-yI)-2 -(3-. N furyl)]-quinazoline- N N 276.30 12 WO 2009/152868 PCT/EP2008/057908 12 [6-(lH-imidazol-1-y)-2-(1,3- N benzodioxol-5-yl)-]quinazoline. N N 316.32 13 o--/ [6-(lH-imidazol-1-yl)-2-(benzofuran- N 5-yl)}quinazoline dihydrochloride tri- 2.HCI.3H 2 0 hydrate. [6-(lH-imidazol-1-yl)-2-(2,3-dihydro- N 1,4-benzodioxin-6-yl)) quinazoline. N N N N 330.35 15 [6-(IH-imidazol-1-yl)-2-(1,3- N benzodioxol-5-yl)]quinoline dihydro- K\N chloride. iN 351.79 16 .2HCI [6-(IH-imidazol-1-yl)-2-phenyl ]quinoline. ~ N~ N271.32 17 [6-(IH-imidazol-l-yl)-2-(4 methoxypheny)]quinoline dihydro chloride. N 3.1 'X 374.27 18 .2HCI / [6-(1H-imidazol-l-yl)-2-(2- N methoxypheny)]quinoline dihydro- N 0 chloride. N3'/4.2'/ 19 2HCI e [6-(1H-imidazol-1-yl)-2-(3- N furyl]quinoline dihydrochloride. N - - 334.20 20 2H1 0 [6-(1H-imidazol- l-yl)-2-(4 fluoropheny)]quinoline dihydrochlo- N r i d e .
F .214C1
F
WO 2009/152868 PCT/EP2008/057908 13 [6-(IH-imidazol-1-yl)-2-(4- N dimethylaminopheny)]quinoline trihy- N drochloride. N 423.77 22 .3HCI 14 NA [6-(lH-imidazol-1-yl)-2-(4 trifluoromethoxypheny)]quinoline di- < -NO hydrochloride N N428.24 23 .2HCI OCF, [6-(lH-imidazol-1-yl)-2-(2-methyl-4 trifluoromethoxypheny)]quinoline di- N hydrochloride N 442.27 24 .2HCi A -CFa [6-(IH-imidazol-1-yl)-2-(4 methansulfonylpheny)]quinoline dihy- N drochloride 422.33 25 .2HC| , o I [6-(2-methyl-IH-imidazol-1-yl)-2-(4- N methoxypheny)jquinoline dihydro chloride N N 388.38 26 N N .2HCI O [6-(2-methyl-IH-imidazol-1-yI)-2-(2- N_ methoxypheny)]quinoline dihydro- NA chloride N0 N 388.38 27 N N .2HCI [6-(4-methyl-]H-imidazol-] -yl)-2- N. (furan-3-yl)-]quinoline dihydrochlo ride N N Ne348.31 28 .2HC 0 [6-(2-methyl-lH-imidazol-1-yl)-2- N (pheny)]quinoline dihydrochloride ON NN358.35 29 .2HCI I WO 2009/152868 PCT/EP2008/057908 14 [6-(4-methyl-1H-imidazol-l-yl)- N 2-phenyl]-quinoline dihydrochloride N N- 285.35 30 .2HCI [6-(4-methyl-1H-imidazol-1-yl)-2-(4 methoxypheny)]quinoline dihydro- N chloride N 388.38 31 2HCl [6-(4-methyl-1H-imidazol-1-yl)-2-(4- N fluoropheny)]quinoline dihydrochlo- N N 376.34 32 .2HCI F [6-(4-methyl-IH-imidazol-1-yl)-2-(4- N methylthiopheny)]quinoline dihydro- N chloride N 404.34 33 .2HC1 S Preparation of the compounds of the invention. Compounds of formula (I) can be prepared, as described in W02008/014822, by reacting a compound of formula (111) with an imidazole derivative of formula (IV) as depicted in Scheme 1, wherein X, W and R 1 have the same meanings as defined above for compounds of formula (I), and Hal is an halogen atom such as fluorine, chlorine, bromine and iodine, typically fluorine or bromine. Scheme 1: R1 HalW NANH Compound of Formula IIl R1 R1 Compound of Formula I (IV) The reaction of a compound of formula (III) can be carried out using an imidazole deriva tive of formula (IV) either as free base or its alkaline metal salt (sodium, lithium or potas sium salt), according to the general reaction conditions described in W02008/014822, or WO 2009/152868 PCT/EP2008/057908 15 more in particular using CuI or Cu 2 O as catalyst, dimethylethylendiamine or 4,7 dimethoxy-1,10-phenantroline as ligands, and diglyme as solvent, caesium carbonate as base, at a temperature of about 150*C for 20-50 hours. When X is a nitrogen atom, compounds of formula (III) can be prepared from known dia mines of formula (V) as depicted in Scheme 2. Scheme 2: Br N HNH 2 I) Cyclization BrN -' N 0 2 2) Oxidation R4 c I R4A Compound of Formula V Compound of Formula III (VI) Br N NN Br 1) Cyclization BN Br N NH 2 N N Z A NH 2 c N z 2) Oxidation A IQ Compound of Fonnula V (Via) Compound of Fonnula III Where Y, Q and Z have the same meanings as for compounds of formula (I), and R4 is any of the substituents above reported as substituents for the aryl group in compounds of for mula (I). Compounds of formula (V) are prepared according to known methods, com pounds of formula (VI) and (VIa) are known compounds, or are prepared according to known methods. Reaction conditions as previously described in W02008/014822 for the cyclization and oxidation steps can be used, however higher yields can be obtained for the most of cases using the reaction conditions reported in Example 1. This improved synthetic procedure also consists of simpler operations, thus giving rise to a more practical synthetic process. Alternatively, a compound of formula (III) where X is a nitrogen atom (-N) can be pre pared by cyclization of the diamine of formula (V) with an orthoester of formula (VII) or (VIIa) as reported in scheme 3. Scheme 3: WO 2009/152868 PCT/EP2008/057908 16 C(OMe) 3 R Br Br N
NH
2 1) Cyclization - NH 2 2) Oxidation Compound of formula V C(OMe) 3 Compound of formula III Br Br NH 2 (Vila) z
NH
2 I) Cyclization Compound of formula V 2) Oxidation Y-Q Compound of formula Ill Wherein R4, Y, Q and Z are as above described. The cyclization reaction of the orthoesters of formula (VII) and (VIla) with the bisamines of formula (V) is carried out in toluene or another inert organic solvent, using acid catalysis, typically p-toluene sulfonic acid, at the reflux temperature for about 50 hrs. The oxidation step can be carried out using MnO 2 in dichloromethane. Alternatively, compounds of formula (I) where X is a nitrogen atom (-N) can be prepared by cyclization of diamine of formula (VIII) with Pinner salts of formula (IX) or (IXa) as reported in Scheme 4. Scheme 4: WO 2009/152868 PCT/EP2008/057908 17 HN OMe R4 N HNH 2 (IX) N N RI N N 2 Ri H NHN ' 1 [NH2R NH 2 ---- 0R1R4 1) Cyclization A Compound of formula VII HN OMe 2) Oxidation .HC Compound of formula I R1 IR1 RIR1 N) N HNH 2 N-0 NRN R N N R1 1 A NH 2 NR AI A N N R1 N N NH z Compound of formula V111 R1H 1) Cyclization NH 2 2) Oxidation Compound of formula I The condensation and cyclization reaction of bisamines of formula (VIII), with Pinner salts of formula (IX), or of formula (IXa), where 14, Y, Q and Z are as above reported, can be obtained by heating the reaction mixture in an alcoholic solvent such as methanol, ethanol or propanol at reflux temperature, for about 1 hour. The formed intermediate amidine is then cyclized to the corresponding dihydroquinazoline by heating in acetic acid, The oxi dation of the dihydroquinazoline intermediate to the corresponding compound of formula (I) is achieved using MnO 2 in an inert organic solvent such as dichloromethane. Pinner salts of formula (IX) and (IXa) are prepared according to known procedures, typi cally by bubbling anhydrous hydrochloric acid in an alcoholic solution of the correspond ing nitrile, at a temperature between -20* and 0*C. The resulting Pinner salt is crystallized from ether, typically tertbutylmethylether. Compounds of formula (VIII) are obtained according to Scheme 5, by reduction of the ni trile of formula (X), which is in turn obtained by reduction of the corresponding nitro derivative of formula (XI), where R, is as for compounds of formula (I). The compounds of formula (XI) are obtained by nucleophilic substitution on 5-fluoro-2-cyano-nitrobenzene with the imidazolyl derivative of formula (IV).
WO 2009/152868 PCT/EP2008/057908 18 Scheme 5: R1 R R1 cNN MH2Ra-N R1 NH I(V I H 2 1( :NH 2 NX (wI) SnC 2 HCI 37% R1 R1 N : R1- N CN R1 NH R1 NO R1 (IV) F ON R1
NO
2 (XI) Catalytical reduction of a compound of formula (X) to provide a compound of formula (VII) can be accomplished using Nickel-Raney as catalyst, at an hydrogen pressure of about 60 bar, in methanol or ethanol containing about 10% of ammonia (gas), at a tempera ture of 30-60*C. Conversion of a cyano-derivative of formula (XI) into a compound of formula (X) can be obtained using SnC1 2 in concentrated HCl at a temperature ranging be tween -10* and 00. Derivatives of formula (XI) are obtained by reaction of 5-fluoro-2 cyano-nitrobenzene with the imidazolyl derivatives of formula (IV), in an organic solvent, typically acetonitrile, at a temperature of 50-90"C. When the R, substituent in the com pound of formula (IV) is in position -4 and the R substituents in the other positions are hydrogen, regioisomers of compounds of formula (XI) could be obtained. These regioi somers can be separated by column chromatography and/or crystallization. Compounds of formula (I) where X is a -CH group, can be prepared from a compound of formula (XII) by reaction with a boronate of formula (XIII) or (XIIIa) as reported in Scheme 6. Scheme 6: WO 2009/152868 PCT/EP2008/057908 19 R1 R1 Ri- N N NZZ Ri1 -N N N OTf (HOB RIW Compound of Fornula XII (XIII) Compound of Formula I R1 R1 R1 - (HO) 2 B z Q r R W N OTt fL N W Compound of Formula XII (XIIla) Compound of Formula I OTf= trifluoromethansulfonate Wherein Ri, 1 4 , W, Y, Z and Q are as above defined. A similar approach which utilizes the Suzuky coupling for preparing compounds of formula (I) as herein defined, but starting from 2-chloro-6-imidazolyl-quinoline derivatives was previously reported in our patent application W02008/014822. However, the use of the triflate group instead of a chloro atom as previously reported, remarkably increases coupling yields, as well as are higher the yields for the preparation of compounds of formula (XII) in comparison with the corre sponding 2-chloroderivatives. The reaction of a compound of formula (XII) with the boro nate of formula (XIII) or (XIIa) is carried out in an inert organic solvent such as toluene, dimethoxyethane or tetrahydrofurane, in the presence of a base such as potassium carbon ate or caesium carbonate, with palladium catalysis. Palladium tetrakistriphenylphosphine or a palladium salt and an appropriate ligand can be used as catalyst. Compounds of for mula (XIII) or (XIlLa) are commercially available compounds or can be prepared according to methods well known in the art. Alternatively, compounds of formula (I) can be obtained by reacting compounds of for mula (XII) with aryl halides, typically aryl bromides, derivatives of formula (XIIb) and (XIIc), according to the Stille reaction (Tetrahedron Letters, 36, 50, 9085, 1995) as de picted in Scheme 6a. Scheme 6a: WO 2009/152868 PCT/EP2008/057908 20 R1 R1 RI (Me) 3 Sn-Sn(Me) R N R1 R1 R1 (Me) 3 Sn-Sn(Me) 3 R N N OTf R W Compound of Formula XII (XIlIc) Compound of Fomula I OTf= trifluoromethansulfonate The reaction can be carried out either with bis-(trimethyl)tin or with bis-(tributyl)tin, using as catalyst: Tetrakis(triphenylphosphine)palladium, or Tris(dibenzylideneacetone)dipalla dium, or Palladium-dichlorobis(triphenylphosphine, in the presence of lithium chloride or potassium fluoride, in a solvent such as dioxane, tetrahydrofurane, dimethoxyethane or toluene. Aryl-bromides of formula (XIIlb) and (XIIIc) are commercially available or can be prepared according to known routes. Compounds of formula (XII) where R 1 , R 4 , W, Y, Z and Q are as above defined, are ob tained as outlined in scheme 7, from 2-quinolinones of formula (XIV). 2-Quinolinones of formula (XIV) are obtained from the corresponding 2-metoxyquinoline derivatives of for mula (XV) which in turn are prepared from the 6-bromo-derivatives of formula (XVI) by reaction with imidazole derivatives of formula (IV). 2-Methoxy-6-bromoquinoline, com pound of formula (XVI), is a known compound (RN: 99455-07-7). Scheme 7: WO 2009/152868 PCT/EP2008/057908 21 Ri- R1i R 1 Ri N 0 N OTf H Compound of Formula XIV Compound of Formula XI z 1 0f= trifluoromethansulfonate R1 N N R1 Br. N~ R1 IV N1 "C ____ N 0 R1 O1 B Compound of Formula XV Compound of Formula XVI Preparation of a compound of formula (XII) from a compound of formula (XIV) can be carried out in pyridine using trifluoromethanesulfonic anhydride or trifluoromethanesul fonyl chloride at 0 0 /-10 0 C, or in dichloromethane using an organic base such as triethyl amine or diisopropylethylamine. Alternatively, bis-trifluoromethylanilide in dimethylfor mamide, using sodium hydride (NaH) as base, can be utilized. Conversion of a compound of formula (XV) into a compound of formula (XIV) is achieved using hydrochloric or hy drobromic acid, at temperatures ranging from 25*C to reflux temperature. Alternatively, BBr 3 in dichloromethane can be used. Compounds of formula (XV) are prepared reacting 6-bromo-2-methoxyquinoline, formula (XVI), with imidazole or substituted imidazoles of formula (IV). The reaction can be carried out using the compounds of formula (IV) as free base or corresponding alkaline metal salt, in the presence of a suitable catalyst, in a solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), acetonitrile, N-methyl pyrrolidone (NMP), dimethoxyethane, tetrahydrofurane (THF), toluene or xylene, at a temperature ranging from 50 *C to reflux temperature. As catalyst a copper catalyst such as Cul, a mixture of Cu/CuO or Cu(OTf) 2 .benzene complex can be used, optionally in the presence of ligands such as 8-hydroxyquinoline, 1,1 0-phenantroline, dimethylethylenedia mine, dibenzylidene acetone. A base such as potassium carbonate, caesium carbonate, triethylammonium carbonate is usually used. Palladium can be also used as catalyst, typi cally the methodology of Buchwald-Hartwig for imidazole addition to aryl bromides, in DMF as solvent, using both Binap [2,2'-bis(diphenylphosphino)-1,1'-binaphtyl] or Dppf [1,3-bis(diphenylphosphinopropane] palladium soluble catalysts, and potassium tert butylate as base under microwave heating, can be used for the preparation of compounds WO 2009/152868 PCT/EP2008/057908 22 of formula (XV). When the imidazole derivative of formula (IV) is substituted (for example R 1 : methyl, trifluoromethyl, hydroxymethyl), compounds of formula (XIV) can be prepared in high yield by cyclization of a compound of formula (XVII) as depicted in scheme 8. Com pounds of formula (XVII) are prepared from anilines of formula (XVIII), which are in turn prepared by reduction of compounds of formula (XIX). Compounds of formula (XIX) are prepared by reacting the commercially available 4-fluoronitrobenzene with imidazoles of formula (IV). Scheme 8: N R1 R1 Ri N x iRI N_ R 1 O R1CO RiN 0 R1 H N 0 H Compound of Formula XV11 Compound of Formula XIV R1 R1 Nz R1 R1 R1 N R1i N R1 PI) F N R1 NH 2 R NO NO 2 Compound of Formula XVmI Compound of Formula XIX Cyclization of a compound of formula (XVII) into a compound of formula (XIV) can be obtained by stirring the enolether in a mineral acid (hydrochloric or sulphuric acid), a tem perature ranging from -10*C to +25*C. Alternatively, the cyclization can be carried out in an inert organic solvent, such as dichloromethane, dimethoxyethane or toluene, using a Lewis acid as catalyst. Compounds of formula (XVII) can be prepared by reacting com pounds of formula (XVIII) with 3-ethoxyacryloyl chloride in pyridine, or in dichloro methane in the presence of triethylamine. Reduction of compounds of formula (XIX) can be obtained using SnCI 2 in an alcohol (ethanol or methanol) or catalytically using hydro gen and Pd/C or PtO 2 as catalyst. Compounds of formula (XIX) are obtained from 4 fluoronitrobenzene and the imidazolyl derivatives of formula (IV) according to methods as above described.
WO 2009/152868 PCT/EP2008/057908 23 Alternatively, a compound of formula (1) where X is either a -CH group or a nitrogen atom (-N) can be prepared from a compound of formula (XX) by reaction with glyoxal or a di carbonyl derivative of formula (XXI) in the presence of formaldehyde or of an aldehyde of formula RICHO and ammonium chloride, as summarized in Scheme 9. Scheme 9: 0 RI R1 RI
H
2 N N X (XXI) 0 RI N
WH
3 PO, RI N RI H NH 4 Cl Compound of Formula XX Compound of Formula I Wherein X, W and R, have the same meanings as discussed above for compounds of for mula (I). Compounds of formula (I), where all R 1 are hydrogen atoms, can be obtained by treating compounds of formula (XX) with glyoxal, in methanol, typically at room temperature, then adding NH 4 Cl and formaldehyde, and heating at reflux, finally phosphoric acid is added. Compounds of formula (I) where the imidazole is substituted, can be prepared using a similar procedure but using a dicarbonyl compound of formula (XXI) (wherein at least one R1 is not hydrogen) instead of glyoxal, an aldehyde of formula RICHO can be used as well (Synthesis, 2003, 2661-2666). Not limiting representative examples for preparations of compounds of Formula (I) are re ported below. Example 1 : [6-(lH-imidazol-l-yl)- 2-phenvilquinazoline. S(Nen NN CuL (6.6 g., 0.034 mol.) and dimethylethylenediamine (8.67 mL, 0.07 mol) were added, WO 2009/152868 PCT/EP2008/057908 24 under inert atmosphere, to 700 mL of diglyme, at room temperature (r.t.). After stirring few minutes a suspension was obtained, to this suspension 6-bromo-2-phenyl-quinazoline (65.2g, 0.228 mol.) and imidazole (31.2g, 0.456 mol., 2 eq.) were added followed by Cs 2
CO
3 (74.7 g., 0.023 mol). The resulting reaction mixture was heated at 150'C, under stirring, for 46 hours. After cooling the reaction mixture was cooled at r.t. and diluted with aqueous saturated NH 4 Cl solution (3.5 L). Ethyl acetate (AcOEt) was added, the organic phase was separated and the aqueous phase extracted with AcOEt, the collected organic phases were washed with water, filtered, dried and concentrated. The residue dissolved in AcOEt/Methanol (MeOH) (95:5) was filtered through silica gel, concentrated and crystal lized from MeOH/hexane to afford the title product (48.7 g, yield 78 %). C 17
H,
2
N
4 ; MW: 272.31; mp 153.8-158.7 *C; 'H-NMR (200 MHz, d 6 -DMSO) 7.23 (s, IH), 7.58-7.62 (m, 3H), 8.00 (s, 1H), 8.23 (d, IH), 8.39-8.63(m, 5H), 9.72(s, 1H). IR (KBr): 1556, 1506, 1379. 6-bromo-2-phenylquinazoline Br To dichloromethane (DCM) (3.5 L), 5-bromo-2-amino-benzylamine (137g, 0.5 mol) and triethylamine (TEA) (250 mL, 1.75 mol) were added at 04C on stirring. Then benzoyl chloride (55 mL, 0.45 mol) in DCM (500 mL) was added on stirring at such a rate to keep the temperature at 0-5*C. The mixture was stirred for 3 hours at r.t.. Water (1 L) was added and the organic phase was separated, washed with water and dried. The solvent was evapo rated and SOCl 2 (100 mL) was added to the residue (147.5 g) suspended in toluene (1.5 L). The obtained suspension was heated at reflux for 72 hours. On cooling a precipitate was formed, it was filtered, washed with toluene and suspended in aqueous ammonia, the sus pension was extracted with AcOEt. The combined organic phases were washed with water, dried and concentrated to afford the dihydroquinazoline derivative, as a light brown solid (93.8 g., 64% yield). The dihydroquinazoline was dissolved in DCM (2 L) and MnO 2 (56.28 g) was added on stirring. The resulting suspension was stirred at r.t. for 18 hours. The suspension was filtered on celite, the cake was washed with DCM and the combined filtrate and washings were concentrated to afford the titled product as an amorphous solid, 85.54 g (60 % overall yield; 95% oxidation yield). C 14
H
9 BrN 2 ; MW: 285.15; MS m/z: 286 WO 2009/152868 PCT/EP2008/057908 25 (M+ 1). 'H-NMR (300 MHz, d 6 -DMSO) ppm: 7.58-7.61 (m, 3H), 8.02 (d, 1H), 8.17 (dd, 1H), 8.49-8.56(m, 3H), 9.70(s, LH). 6-bromo-2-phenvlquinazoline (cyclization using trimethylbenzoic orthoester) Br N ' To toluene (200 mL), 5-bromo-2-amino-benzylamine (9.5 g, 47.2 mmol) and trimethyl benzoic orthoester (8.2 g, 47.2 mmol) were added, followed by p-toulensulfonic acid (1.35 g, 7.1 mmol). The resulting suspension was stirred at reflux for 50 hours. The reaction mixture was cooled at r.t., diluted with AcOEt (150 mL), washed with saturated sodium bi carbonate, then with water. The organic layer was dried and concentrated to provide the in termediate dihydroquinazoline as a light brown solid (8.5 g; 63%). This intermediate is dissolved in DCM (20 mL) at r.t., then MnO 2 (5.1 g ) was added. The resulting mixture was stirred at r.t. for 48 hrs, then filtered on celite. The filtrate was concentrated to provide the title product as white solid ( 8.1 g, 95%). C 14 H9BrN 2 ; MW: 285.15; MS m/z: 286 (M+ 1). 'H-NMR (300 MHz, d 6 -DMSO) ppm: 7.58-7.61 (m, 3H), 8.02 (d, 1H), 8.17 (dd, 1H), 8.49-8.56(m, 3H), 9.70(s, 1H). 5-bromo-2-amino-benzylamine Br HNH 2
NH
2 A solution of borane in THF (1 M, 400 ml) was added at 0 *C to a suspension of 5-bromo anthranilonitrile (60 g, 0.304 mol, prepared as described in S. M. Mackenzie et al, J. Chem. Soc. C, 1970, 17, 2298-2308) in THF (450 L), under N 2 . The mixture was stirred for 72 hours at r.t.. After cooling at 0 'C absolute EtOH was added, then HCI was bubbled through the solution. The mixture was concentrated and the residue was suspended in iso propyl ether. The obtained solid was dried to give the di-hydrochloride of the title product (76.6 g, 91.4% yield). C 7
H
9 BrN 2 . 2HCl, MW 273.9; 'H-NMR (200 MHz, d 6 -DMSO) ppm: 4.13 (s, 2H); 5,82 (s, 4H), 7.24 (d, IH), 7.55 (dd, 1H), 7.73 (s, 1H), 8.57 (s, 2H). Since the free base is used in the cyclization step, the hydrochloride was suspended in aqueous am monia, stirred for some minutes after that the free base precipitates. The solid is filtered and dried (yield is quantitative).
WO 2009/152868 PCT/EP2008/057908 26 Example 2: [6-(2-methyl- 1 H-imidazol- 1 -vl)-2-phenylliuinazoline N N N N 6-bromo-2-phenyl-quinazoline (1.43 g, 5.0 mmol) and 2-methylimidazole (0.50 g, 6 mmol) were mixed with PEG 400 (d:1.126, 1.0 g, 885 ptL) and 4,7-dimethoxy-1,10-phenantroline (186 mg, 0.75 mmol), to this mixture CuzO (38.5 mg, 0.25 mmol) and Cs 2
CO
3 (2.29 g, 7.0 mmol) were added. The resulting reaction mixture was heated at 11 0*C, under argon at mosphere, for 24 hours. After cooling at r.t., the mixture was diluted with DCM (50 mL) and filtered over celite, the cake was washed with DCM and the combined filtrate and washings were evaporated to dryness. The residue was purified by chromatography (SiO 2 , EtOAc/MeOH 95.5). The pure title compound was isolated as pale yellow solid, 1.02g (yield: 71%), m.p.: 198.3-200.31C. Ci 8
HI
4
N
4 , MW:286.34; MS: m/z 287 (M+H); 'IH-NMR (200 MHz, d 6 -DMSO) ppm: 2.40 (s, 1H), 7.0 (s, IH), 7.40 ( s, lH), 7.60 (m, 3H), 8.10 8.30 (m, 3H), 8.60 (m, 2H), 9.80(s, 1H). Alternatively 6-(2-methyl-1H-imidazol-1-yl)-2-phenyl-quinazoline can be prepared from 4-(4-methyl- 1 H-imidazol- 1 -yl)-2-aminomethylaniline: Example 2 (B): 6-(2-methyl-1H-imidazol-1-yl)-2-phenyl-quinazoline (alternate route) 4-(2-methyl-1H-imidazol-1-yl)-2-aminomethylaniline (2.0 g, 10 mmol) and methyl ben zimidate hydrochloride (3.5 g, 20 mmol; RN: 5873-90-5, Aldrich) were dissolved in methanol (50 mL), the resulting mixture was heated at reflux for 2 hours, during this time the aminomethyl-derivative was converted into the corresponding benzamidine. After that, the methanol was evaporated and the residue taken up with glacial acetic acid (50 mL), the reaction mixture was heated at rerflux for 1.5 hours. After cooling at r.t. the reaction mix ture was diluted with toluene (50 mL) and evaporated. The residue was taken up with AcOEt (400 mL), washed with aq. ammonia, with water, then dried and concentrated. The obtained oily residue was dissolved in DCM (400 mL) and MnO 2 ( 6.0 g, 70 mmol) was added at r.t., in three portions, over 2 hours. The resulting suspension was stirred at r.t. for WO 2009/152868 PCT/EP2008/057908 27 24 hrs, then filtered over celite and the cake was rinsed with DCM. The combined filtrate and washings were concentrated and the residue chromatographed over silica gel (DCM/MeOH/NH 3 , 85:25.2) the appropriate combined fractions were evaporated and the residue taken up with ethyl ether, heated at reflux for 5 minutes then cooled at 25*C to crystallize the titled product as slightly brown powder (2.0 g; yield: 74%). CI 8 H 14
N
4 , MW: 286.34; MS: m/z 287 (M+H); 'H-NMR (200 MHz, d 6 -DMSO) ppm: 2.40 (s, 1H), 7.0 (s, 1H), 7.40 (s, 1H), 7.60 (m, 3H), 8.10-8.30 (m, 3H), 8.60 (m, 2H), 9.80 (s, 1H). Example 3: [6-(2-methyl-1H-imidazol-1-yl)-2-(4-methoxyphenyl)]quinazoline N " N N Analogously prepared in 69% yield, starting from 4-(2-methyl-1H-imidazol-1-yl)-2-amino methylaniline (2.0 g, 10 mmol) and methyl (4-methoxy)benzimidate hydrochloride. Slight grey powder, mp.: 198.3-200.3*C. C 19
H
16
N
4 0, MW: 316.37. MS: m/z 317 (M+1).'H-NMR (200 MHz, d-DMSO) ppm: 2.42 (s, 3H), 3.33 (s, 3H), 7.01 (s, 1H), 7.50 (s, 1H), 7.59-7.63 (m, 2H), 8.11-8.32 (m, 3H), 8.58-8.63 (m, 2H), 9.79 (s, 1H). FT-IR (ATR) cm': 1624, 1588, 1557, 1496, 1414, 1300, 1271, 1165, 843, 761. 4-4-methyl- 1H-imidazol- 1 -yl)-2-aminomethylaniline dihydrochloride N H2CNH2 .2 HCI NH 2 To 4-(2-methyl-1H-imidazol-1-yl)-2-cyanoaniline (7.8 g; 39 mmol) dissolved in 10%
NH
3 /methanol (70 mL) was added Raney-Nichel (2 g), the resulting mixture was hydro genated at 60'C, at an hydrogen pressure of 60 bar, for 12 hours. The nitrogen purged reac tion mixture was filtered on celite, the cake was washed with methanol and the combined filtrate and washings evaporated, the residue was dissolved in methanol, filtered and HCI was bubbled at 0"C to provide the title product as yellow-orange solid (6.1 g, 60 %).
C
io
H
12
N
4 .2HCI MW 263.23. MS: m/z 202 (M+1).
1 H-NMR (300 MHz, CDC3) ppm: 2.20 WO 2009/152868 PCT/EP2008/057908 28 (s, 3H), 3.64 (s, 2H), 5.35 (s, 2H), 6.68 (d, 1H), 6.82 (d, 1H), 6.94 (dd, IH), 7.05-7.07 (m, 2H). The free base used in the above step was obtained by suspending the dihydrochloride in concentrated ammonia, stirring the suspension 5 min. then filtering the precipitate which was washed with water and dried. 4-(2-methyl- I H-imidazol- 1 -yll-2-cyanoaniline N( CN
NH
2 SnCI 2 .2H 2 0 (60.0 g; 0.26 mol) was dissolved in 37% HCl (100 mL), to this solution cooled to -10*C, 4-(2-methyl-1H-imidazol-1-yl)-2-cyano-nitrobenzene (12.0 g, 50 mmol) was added in two portions over the course of 30 min.. Completed the additions the stirred reaction mixture was allowed to come to r.t., and after further 45 min. stirring, it was poured in ice/water (250g) and 3N KOH (500 mL). The resulting suspension was filtered and the cake washed with water. The residue was suspended in 2M NH 3 /EtOH (250 mL), stirred for a few minutes and filtered, the filtrate was concentrated to provide the titled compound as a brown solid (8 g, 78 %). C 11 HioN 4 , MW: 198,23. MS: m/z 199 (M+1).
1
H
NMR (300 MHz, CDC1 3 ) ppm: 2.21 (s, 3H), 4.70 (s, 2H), 6.79 (d, 1H), 6.97 (d, 1H), 7.22 (dd, 1H), 7.29 (d, 1H). 4-(2-methyl- I H-imidazol- I -yl)-2-cyanonitrobenzene. N _ N CN
NO
2 2-cyano-4-fluoronitrobenzene (9.8 g, 59 mmol) and 2-methylimidazole (14.5 g, 177 mmol) were dissolved in dry acetonitrile (300 mL), the reaction mixture was then heated at 90'C for 5 hours. The solution was cooled at r.t. and the solvent evaporated, the residue was partitioned be tween AcOEt/0.5N HCl (5/1), the separated organic phase was washed with water, brine and then evaporated. The orange residue was crystallized from acetone/hexane to provide 12.8 g (95%) of the titled compound. When not dry acetonitrile is used some amide is ob- WO 2009/152868 PCT/EP2008/057908 29 tained as side-product. 'H-NMR (300 MHz, CDC1 3 ) ppm: 2.47 (s, 3H), 7.70 (d, IH), 7.12 (d, IH), 7.73 (dd, 1H), 7.83 (d, 1H), 8.46 (d, 1H). Example 4: F6-(4-methyl-IH-imidazol-1-yl)-2-phenyllquinazoline N 4-(4-methyl-1H-imidazol-1-yl)-2-aminomethylaniline (2.0 g, 10 mmol) and methyl ben zimidate hydrochloride (1.73 g, 10 mmol; RN: 5873-90-5, Aldrich) were dissolved in methanol (15 mL), the resulting mixture was heated at reflux for 2 hours, during this time the aminomethyl-derivative was converted into the corresponding benzamidine. After that, methanol was evaporated and the residue taken up with glacial acetic acid (15 mL), the re action mixture was heated at reflux for 2 hours. After cooling at r.t. the reaction mixture was diluted with toluene (50 mL) and evaporated. The residue was taken up with AcOEt (200 mL), washed with aq. ammonia and then with water, dried and concentrated. The oily residue was dissolved in DCM (200 mL) and MnO 2 (6.0 g, 70 mmol) was added at r.t., in three portions, over 2 hours. The resulting suspension was stirred at r.t. for 22 hrs, then fil tered over celite, and the cake was rinsed with DCM. The combined filtrate and washings were concentrated and the residue was taken up with ethyl ether, heated at reflux for 5 minutes then cooled at 25*C, to crystallize the title product as off white powder (2.3 g; yield: 85%), melting at 201.9-202.8 0 C. CisH 14
N
4 , MW: 286.34. MS: m/z 287 (M+H); IH NMR (400 MHz, d 6 -DMSO) ppm: 2.21 (s, 3H), 7.57-7.60 (m, 3H), 7.65 (s, IH), 8.17 (d,lH), 8.33-8.38 (m, 3H), 8.54-8.58 (m, 2H), 9.68 (s, lH). FT-IR (ATR) cm': 1626, 1585, 1555, 1503, 1442, 1390, 1253, 1060, 838, 711. Example 5: [6-(5-methyl- I H-imidazol- I -vl-2-phenylluinazoline N
NX
WO 2009/152868 PCT/EP2008/057908 30 Analogously prepared in 74% yield, starting from 4-(5-methyl-IH-imidazol-1-yl)-2 aminomethylaniline (2.0 g, 10 mmol) and methyl benzimidate hydrochloride (1.73 g, 10 mmol). Light brown powder, mp.: 138.5-139.1"C. C 18
H,
4
N
4 , MW: 286.34. MS: m/z 287 (M+H); 'H-NMR (400 MHz, d 6 -DMSO) ppm: 2.27 (s, 3H), 6.91 (s, 1H), 7.58-7.60 (m, 3H), 8.11 (s,1H), 8.21 (s, IH), 8.25 (m, lH), 8.29 (s, 1H), 8.58 (m, 2H), 9.78 (s, 1H). FT-IR (ATR) cm- 4 : 1588, 1554, 1490, 1437, 1382, 1232, 1167, 919, 812, 763, 709. Example 6: [6-(4-methl-1H-imidazol-1 -yl)-2-(4-methoxyphenyl)Iquinazoline N NN N 0 Analogously prepared in 76% yield from 4-(4-methyl-IH-imidazol-1-yl)-2-amino methylaniline and methyl 4-methoxybenzimidate hydrochloride (RN: 39739-49-6). Col ourless crystals, mp.: 201.0-202.0 0 C. C19Hi 6
N
4 0, MW: 316.37; MS: m/z 317 (M+H); 'H NMR (400 MHz, d 6 -DMSO) ppm: 2.21 (s, 3H), 3.85 (s, 3H), 7.10 (d, 2H), 7.62 (s, 1H), 8.11 (d,lH), 8.28-8.33 (m, 3H), 8.49 (d, 2H), 9.61 (s, IH). FT-IR (ATR) cm-1: 1627, 1580, 1515, 1388, 1377, 1252, 1167, 1017, 836. Example 7: [6-(4-methyl-1H-imidazol-1-y1)-2-(2-methoxyphenyllquinazoline N - N " N 0 N I
.
Analogously prepared from 4-(4-methyl-1H-imidazol-1-yl)-2-aminomethylaniline and methyl 2-methoxybenzimidate hydrochloride, in 65% yield. Colourless crystals, mp.: 160.6-162.0*C. C 9
H
16
N
4 0, MW: 316.37; MS: m/z 317 (M+H); 'H NMR (400 MHz, d DMSO) ppm: 2.21 (s, 3H), 3.79 (s, 3H), 6.98 (d, 1H), 7.08 (t, 1H), 7.11 (d, 1H), 7.50 (t, 1H), 7.63- 7.67 (m, 2H), 8.14 (d, IH), 8.27 (d, IH), 8.33-8.40 (m, 1H), 9.64 (s, 1H). FT-IR (ATR) cmi: 1560, 1507, 1398, 1243, 1060, 1023, 847, 761.
WO 2009/152868 PCT/EP2008/057908 31 Example 8: [6-(4-methyl-1H-imidazol-1-yl)-2-(3-methoxyphenyl)]guinazoline N N Analogously prepared from 4-(4-methyl-1H-imidazol-1-yl)-2-aminomethylaniline and methyl 3-methoxybenzimidate hydrochloride, in 68% yield. Light yellow powder, mp.: 294-296"C. C 19
H
16
N
4 0, MW: 316.37; MS: m/z 317 (M+H); 1 H NMR (400 MHz, d DMSO) ppm: 2.22 (s, 3H), 4.09 (s, 3H), 7.16 (dd, 1H), 7.50 (t, 1H), 7.64 (s, 1H), 8.11 (s, 1H), 8.18 (t, 2H), 8.35-8.40 (m, 3H), 9.69 (s, 1H). FT-IR (ATR) cm~1: 1627, 1556, 1487, 1451, 1384, 1269, 1211, 1036, 836, 774, 719. Example 9: [6-(4-methyl-1H-imidazol-1-yl)-2-(1,3-benzodioxol-5-yl)quinazoline N '-N -"0 Analogously prepared in 54% yield from 4-(4-methyl-1H-imidazol-1-yl)-2-aminome thylaniline and methyl 1,3-methylendioxybenzimidate hydrochloride. Colourless crystals, mp.: 215.3-218.7*C. C 19
H
1 4
N
4 0 2 , MW: 330.35; MS: m/z 331 (M+H); 1H NMR (400 MHz, d 6 -DMSO) ppm: 2.36 (s, 3H), 6.15 (s, 2H), 6.98 (d, 1H), 7.14 (s, 1H), 7.84 (s, 1H), 7.94 (m, 2H), 8.13 (s, 1H), 8.15 (d, IH), 8.27 (d, 1H), 9.45 (s, 1H). FT-IR (ATR) cm-': 1557, 1503, 1444, 1380, 1248, 1036, 826. Example 10: [6-(4-methyl-IH-imidazol-1-yl)-2-(4-fluorophenl)lquinazoline Nm N NN NNF Analogously prepared in 58% yield, from 4-(4-methyl-1H-imidazol-1-yl)-2-aminome thylaniline and methyl 4-fluorobenzimidate hydrochloride,. CisH 1 3
N
4 F, MW: 304.33; MS: m/z 305 (M+H); 1 H NMR (300 MHz, CDCl 3 ) ppm: 2.38 (s, 3H); 7.18-7.38 (m, 4H), 7.82 7.95 (m, 3H), 8.6-8.7 (m, 2H), 9.50 (s, 1H). FT-IR (ATR) cm: 1627, 1602, 1556, 1579, WO 2009/152868 PCT/EP2008/057908 32 1512, 1504, 1446, 1390, 1374, 1217, 1159, 1065, 836, 825, 735, 714. Example 11: [6-(4-methyl-IH-imidazol-1-y11-2-(4-methanesulfonylphenylllquinazoline N N-O ;N Analogously prepared in 38% yield from 4-(4-methyl-1H-imidazol-1-yl)-2-aminomethyl aniline and methyl 4-methanesulfonylbenzimidate hydrochloride, mp.: 276.4-281.7 0 C. C19H 16
N
4 0 2 S, MW:364.43; MS: m/z 365 (M+H); 'H NMR (300 MHz, CDC1 3 ) ppm: 2.39 (s, 3H); 3.10 (s, 3H), 7.20 (s, 1H), 7.90-8.10 (m, 4H), 8.20 (dd, 4H), 8.85 (d, 2H), 9.60 (s, IH). 'H NMR (400 MHz, CDC1 3 ) ppm: 2.38 (s, 3H); 3.15 (s, 3H), 7.21 (s, IH), 7.93 (s, 1H), 7.97 (s, IH), 7.98 (dd, 1H), 8.14 (d, 1H), 8.26 (d, 1H), 8.87 (d, IH), 9.57 (s, 1H). Example 12: [6-(4-methyl-IH-imidazol-l-vl-2-(3-fur1)quinazoline N N 0 Analogously prepared from 4-(4-methyl-1H-imidazol-1-yl)-2-aminomethylaniline and 3 furanecarboximidic acid methyl ester hydrochloride, in 33% yield, mp.: 160.5-163.2*C. Ct 6
H
12
N
4 0, MW: 276.30; MS: m/z 277 (M+H); 'H NMR (300 MHz, CDC 3 ) ppm : 2.35 (s, 3H); 7.15 (d, 2H), 7.51 (s, IH), 7.80 (s, 1H) 7.90-7.95 (m, 2H), 8.10 (d, 1H), 8.40 (s, 1H), 9.40 (s, IH). 1 H NMR (400 MHz, d-DMSO) ppm: 2.21 (s, 3H); 7.17 (s, 1H), 7.63 (s, 1H), 7.87 (m, LH) 8.08 (d, lH), 8.31 (dd, IH), 8.35 (s, 1H), 8.56 (s, 1H), 9.57 (s, 1H). FT IR (ATR) cmf: 1629, 1588, 1576, 1558, 1501, 1379, 1148, 1059, 1007, 862, 815, 723. 4-(4-methyl- 1 H-imidazol- 1 -yl)-2-aminomethylaniline N
NH
2 To 4-(4-methyl-1H-imidazol-1-yl)-2-cyanoaniline (15.5g; 78.2 mmol) dissolved in 10%
NH
3 /methanol was added Raney-Nichel (5 g), the resulting mixture was hydrogenated at WO 2009/152868 PCT/EP2008/057908 33 60"C, at an hydrogen pressure of 60 bar, for 24 hours. The nitrogen purged reaction mix ture was filtered on celite, the cake was washed with methanol and the combined filtrate and washings evaporated. The residue was purified by column chromatography over silica gel (DCM/MeOH/ 2M NH 3 , 85:10:5) evaporation of the combined appropriate fractions af forded the pure titled product as yellow-orange solid (12.9 g, 82%). C 11 H1 4
N
4 , MW: 202.26; 'H-NMR (300 MHz, d,-DMSO) ppm: 2.13 (s, 3H), 5.24 (s, 2H), 6.67 (d, 1H), 7.08 (dd, IH), 7.17 (t, 1H), 7.23 (d, 1H), 7.81 (d, 1H). 4-(5-methyl-1H-imidazol-1-vll-2-aminomethylaniline N NH2 Prepared in 66% yield as above described, starting from 4-(5-methyl-IH-imidazol-1-yl)-2 cyanoaniline. C 1
H
1 4
N
4 , MW: 202.26; 'H-NMR (300 MHz, d 6 -DMSO) ppm: 2.07 (s, 3H), 5.38 (s, 2H), 6.89 (d, 1H), 6.73 (t, 1H), 6.94 (dd, 1H), 7.06 (d, IH), 7.53 (d, 1H). 4-(4-methyl- 1 H-imidazol- I -yl)-2-cyanoaniline ON ' N CN
NH
2 SnCI 2 .2H 2 0 (119.0 g; 0.526 mol) was dissolved in 37% HCl (240 mL), to this solution cooled to -10C, 4-(5-methyl-1H-imidazol-1-yl)-2-cyano-nitrobenzene (24.0 g, 105.0 mmol) was added in five portions over the course of 20 min.. Completed the additions, the stirred reaction mixture was allowed to come to r.t., and after further 45 min. stirring, it was poured in ice/water (500g) and 3N KOH (1.0 L). The resulting suspension was filtered and the cake washed with water, the residue was suspended in 2M NH3/EtOH (250 mL), stirred for few minutes and filtered, the filtrate was concentrated to provide the titled com pound as a brown solid (15.9g, 76%). C 11
HION
4 , MW: 198.23; 'H-NMR (300 MHz, CDC1 3 ) ppm: 2.2(s, 3H), 6.79 (d, 1H), 6.81 (d, 1H), 6.84 (t, 1H), 7.75 (dd, 1H), 7.28 (d, 1H), 7.30-7.34 (m, 1H), 7.57 (d, IH). 4-(5-methyl-1H-imidazol-1-yl)-2-cyanoaniline WO 2009/152868 PCT/EP2008/057908 34 N N CN
NH
2 Prepared in 64% yield as above described, starting from 4-(5-methyl-IH-imidazol-1-yl)-2 cyanonitrobenzene. CJIH 1
ON
4 , MW: 198.23; 'H-NMR (300 MHz, CDC 3 ) ppm: 2.09(s, 3H), 6.81-6.84 (m, 2H), 7.20 (dd, 1H), 7.26 (d, 1H1), 7.44 (d, IH). 4-(4-methyl- 1 H-imidazol- I -yl)-2-cyanonitrobenzene N CN No 2 2-cyano-4-fluoronitrobenzene (29.5 g, 177.6 mmol) and 4-methylimidazole (29.1g, 354.4 mmol) were dissolved in acetonitrile (300 mL), the reaction mixture was then heated at 90'C for 3 hours. The solution was cooled at r.t. and the solvent evaporated, the residue (constituted of about 85:15 regioisomeric mixture of 4/5 methyl-isomers) was partitioned between AcOEt/H 2 0 (5/2), the separated organic layer was washed with water, brine and then evaporated. The orange residue was crystallized from acetone/heptane, This gave a first crop of the titled product 25.0 g (62%), the mother liquor was concentrated and the residue was chroma tographed over silica gel (acetone/heptane 1:3 to 1:1, to 3:1) to provide further 7.0 g (17.2%) of the pure title compound. TLC: (SiO 2 , 245 nm) acetone/heptane (3:1) Rf: 0.50; C 11
H
10
N
4 0 2 , MW: 230.23; 'H-NMR (300 MHz, CDC1 3 ) ppm: 2.3 (s, 3H), 7.10 (t, 1H), 7.63 (d, 1H), 7.75 (dd, IH), 7.86 (d, 1 H), 7.91 (d, 1H), 8.44 (d, IH). 4-(5-methyl-1H-imidazol-1-yl)-2-cyanonitrobenzene. N N CN
NO
2 Obtained from the column chromatography above described as yellow-orange solid (7.2 g; 17.8%).
WO 2009/152868 PCT/EP2008/057908 35 TLC: (SiO 2 , 245 nm) acetone/heptane (3:1) Rf: 0.30; C 11 HioN 4 0 2 , MW: 230.23; 'H-NMR (300 MHz, CDCL 3 ) ppm: 2.3 (s, 3H), 7.0 (t, 1H), 7.63 (d, 1H), 7.74 (dd, IH), 7.84 (d, 1H), 8.49 (d, IH). General procedure for the preparation of iminoester hydrochlorides Iminoester hydrochlorides used as reagents in this invention can be prepared according to procedures well known in literature, for example: J. Org. Chem. 69(20), 6572-6589; 2004, J. Med. Chem., 38(8), 1287-94; 1995, below two representative procedures are herein re ported as examples. Methyl 4-methoxybenzimidate hydrochloride H N! .HCI HN 4-methoxybenzonitrile (12.5 g, 91.1 mmol) was dissolved in methanol (140 mL), through this cooled (-5*C) solution gaseous HCI was bubbled for about 3 hours. The reaction mix ture was then stirred, in a closed flask, at r.t. for 24 hours. Then the excess HC1 was stripped by bubbling nitrogen and the resulting solution was concentrated, the residue was taken up with TBME (100 mL) and stirred for 30 min., then filtrated and dried to provide the title product as a colourless powder 19.0 g (quantitative). C 9
H
11 N0 2 .HCI, MW:201.69 'H-NMR (300 MHz, D 2 0) ppm; 4.20 (s, 3H), 6.9 (m, IH); 7.65 (m, 1H); 8.40 (m, 1H). 3-Furanecarboximidic acid methyl ester hydrocloride 0 NH.HCI 3-Furonitrile (1.0 g; 10.8 mmol) was dissolved in dry MeOH (12 mL), the solution was cooled at -5*C and gaseous HCI was bubbled for 30 min., then the reaction vessel was closed, the temperature allowed to come to r.t. and the reaction mixture stirred overnight. The excess HCl was removed by bubbling nitrogen, then the solvent was evaporated and the residue suspended in TBME (30 mL), filtered and dried to provide the title product, WO 2009/152868 PCT/EP2008/057908 36 1.09 g (63%). C 6
H
7
NO
2 .HCI, MW: 161.59; 'H-NMR (300 MHz, D 2 0) ppm: 3.80 (s, 3H), 4.20 (s, 3H), 7.0 (d, 2H); 7.90 (d, 2H). Example 13: [6-(1H-imidazol-1-yI)-2-(1,3-benzodioxol-5-yl)lquinazoline Nm N 0 0-/ A suspension of 6-amino-2-(1,3-benzodioxol-5-yl)-quinazoline (2.5 g, 9.4 mmol) (W02008/014822) and 40% aqueous glyoxal (1.1 ml, 9.4 mmol) in methanol (20 ml) was stirred at r.t. for 18 h.. NH 4 CI (1.0 g, 0.019 mol), 37% aqueous formaldehyde (1.4 ml, 19 mmol) and methanol (200 ml) were added and the mixture was refluxed for I h. 85%
H
3
PO
4 (1.4 ml) was added and the mixture was heated at reflux for a further 4 h. The sol vent was removed and the residue was poured in water, and basified with aq. NaOH. The precipitate was filtered, washed with water and dissolved in DCM. The product was ex tracted with diluted aqueous HCL. To the collected aqueous layers Na2CO3 was added and the resulting mixture extracted with chloroform, which was washed with water and dried, concentrated and the resulting solid was suspended in isopropyl ether. The solid was fil tered and dried to afford the title product (2.0 g, 29% yield). C 1 H1N 4 0 2 , MW: 316.32. mp 217-218 *C. 'H NMR (200 MHz, d 6 -DMSO) ppm: 6.16 (s, 2H); 7.12 (d, 1H), 7.21 (s, 1H), 8.00 (d, 2H), 8.14-8.22 (m, 2H), 8.36-8.50 (m, 3H), 9.65 (s, 1H). FT-IR (KBr) 1504, 1446, 1251. Example 14: r6-(1H-imidazol-1-vl)-2-(benzofuran-5-yl)-1iuinazoline dihydrochloride tri hydrate Nm .2HCI.3H20 N N N 0 Was analogously prepared in 20% yield starting from 6-amino-2-(benzofurane-5-yl) quinazoline (W02008/014822). C 19 Hi 2
N
4 0. 2HCl. 3H20; MW: 439.30; mp 284.7-285.1 0C; 'H NMR (200 MHz, d 6 -DMSO) ppn: 7.15 (s, 1H); 7.78 (d, 1H),8.02 (s, 1H), 8.10 (d, WO 2009/152868 PCT/EP2008/057908 37 1H), 8.29 (d, IH), 8.47 (m, 2H), 8.58 (d, IH),8.71 (d, IH), 8.90 (s, 1H), 9.78 (s, IH),10.00 (s, iH). FT-JR (KBr): 3399, 3097, 1614. Example 15: [6-(1H-imidazol-] -yl)-2-(2,3-dihydro-1,4-benzodioxin-6-vi)lquinazoline N N N Was analogously prepared in 25% yield starting from 6-amino-2-(2,3-dihydro-1,4-benzo dioxin-6-yl)-quinazoline (W02008/014822), C 19
H
14
N
4 0 2 , MW: 330.35; mp 131.5-131.9 0 C; 'H NMR (200 MHz, d 6 -DMSO) ppm: 4.34 (s, 4H), 7.04 (d, iH), 7.21 (s, 1H), 7.97 (d, iH), 8.03-8.13 (m, 2H), 8.18 (s, 1H), 8.32-8.43 (m, 2H), 8.49 (s, 1H), 9.64 (s, IH). FT-IR (KBr) 1555, 1507, 1286. Example 16: (6-( 1H-imidazol-1-vl)-2-(I ,3-benzodioxol-5-vl)luinoline dihydrochloride N N 2.HCI o 6-(LH-imidazol-1-y)-2-(trifluoromethane sulfonoxy)quinoline (3.0 g; 8.6 mmol), K 2 C0 3 (1.73 g; 10.4 mmol), 3,4-methylendioxyphenylboronic acid and tetrakis-triphenylphosphi ne palladium (0.8g; 0.8 mmol) were mixed under stirring, in dry toluene (100 mL), under argon atmosphere, at r.t.. The resulting reaction mixture was heated at reflux for 15 hours, then it was cooled at r.t. and poured in water (250 mL). The resulting precipitate was fil tered, washed with water, dried and dissolved in DCM/MeOH (9:1, 10 mL,), gaseous HCI was boubled through the solution until formation of a precipitate, which was filtered and dried. The title product was obtained as di-hydrochloride (2.57 g; 88% yield) melting at : 314.0-315 0 C. Ci 9
H
13
N
3 0 2 .2HCl, MW: 351.79. 'H-NMR (200 MHz, d 6 -DMSO) ppm: 6.05 (s, 2H), 7.07 (d, IH), 7.70-7.72 (m, 3H), 8.01-8.29 (m, 5H), 8.51 (d, iH), 9.46 (s, IH). FT IR(ATR)cm: 1602, 1495, 1443, 1265, 1254, 1110,1029,812. Example 17: [6-(1H-imidazol-1-vl)1-2-(phenyl)luinoline WO 2009/152868 PCT/EP2008/057908 38 N N N N Analogously prepared as colorless solid (2.7 g; yield: 89 %) using phenylboronic acid in the Suzuky coupling. Crystallized from DCM/methanol as dihydrochloride, the free base was obtained by suspending the dihydrochloride in conc. aq. ammonia, and the precipitate was filtered, washed with water and dried. Colorless solid (2.3 g) melting at: 130.6 131.4 0 C. C 18
H
3
N
3 , MW 271.32. 'H-NMR (200 MHz, d6-DMSO) ppm: 7.20 (m, lH), 7.75-7.63 (m, 3H), 7.94 (m, 1H), 8.11-8.32 (m, 5H), 8.46-8.50 (m, 2H). FT-IR (ATR) cm~ 1:1625, 1598, 1500, 1325, 1244, 1054, 826, 758, 655. Example 18: [6-(IH-imidazol-1-yl)-2-(4-methoxyphenyl)lquinoline dihydrochloride N 2 HCI 0 Analogously prepared in 57% yield using 4-methoxyphenylboronic acid in the Suzuky coupling, colorless solid, crystallized from DCM/methanol, mp.: 266.0-267.0*C.
C
19 Hi 5
N
3 0.2HCl; MW: 374.27. 'H-NMR (200 MHz, d 6 -DMSO) ppm: 3.84 (s, 3H), 7.14 (d, 2H), 7.87 (s, 1H), 8.11-8.27 (m, 6H), 8.41 (s, 1H), 8.58 (d, lH), 9.70 (s, 1H). FT-IR (ATR) cm 1 : 1597, 1510, 1272, 1184, 1014, 825, 804. Example 19: [6-(1H-imidazol-1-l)-2-(2-methoxyphenvl)]quinoline dihydrochloride N N N0 .2 HCI Analogously prepared in 48% yield, using 2-methoxyphenylboronic acid in the Suzuky coupling, colorless solid, crystallized from DCM/MeOH, mp.: 251.5-252.0 0 C. Ci 9
H
1 5
N
3 0.2HCl, MW: 374.27. 'H-NMR (200 MHz, D 2 0) ppm: 3.87 (s, 3H), 7.10-7.18 (m, 2H), 7.40-7.68 (m, 4H), 7.70-7.90 (m, 5H), 8.94 (s, 1H). FT-IR (ATR) cm-1: 1607, WO 2009/152868 PCT/EP2008/057908 39 1577, 1497, 1317, 1252, 1016, 828, 764, 745. Example 20: [6-(1H-imidazol-1-yll-2-(3-furyl)]quinoline dihydrochloride N ~N .2HCI Analogously prepared in 81.5% yield, using 3-furylboronic acid in the Suzuky coupling. Crystallized from DCM/MeO as colorless solid, mp.: 293.1-295.6*C. C 16
H
1
N
3 0.2HCI, MW: 334.20. 'H-NMR (200 MHz, d6-DMSO) ppm: 7.30 (s, 1H), 7.86-7.90 (m, 2H), 8.1 (d, 1H), 8.15 (dd, 1H), 8.32 (d, 2H), 8.45 (d, 1H), 8.58 (d , IH), 8.68 (s, lH), 9.76 (s, 1H4). FT-IR (ATR) cm': 1651, 1624, 1547, 1328, 1159, 822. Example 21: [6-(1 H-imidazol- 1-yl)-2-(4-fluorophenyl)]quinoline dihydrochloride N
N
.2H-I Analogously prepared in 64.5% yield, using 4-fluorophenylboronic acid in the Suzuky coupling. Crystallized from DCM/MeOH, colorless solid, mp.: 280.7-282.0*C. CigH 12
FN
3 .2HCI, MW: 362.31. H-NMR (200 MHz, d-DMSO) ppm: 7.42 (t, 2H), 8.03 (s, IH), 8.22-8.61 (m, 8H), 9.94 (s, 1H). FT-IR (ATR) cm 1 : 1644, 1599, 1509, 1327, 1248, 1161, 833. Example 22: [6-(1H-imidazol-1-y)-2-(4-dimethylaminophenyl)]quinoline trihydrochloride NN
N
A N N .3HCI Analogously prepared as colorless solid (yield: 84.5%) using 4-dimethylaminophenylboro nic acid in the Suzuky coupling. Crystallized from DCM/MeOH pale red solid, mp.: 284 286 0 C. C 2 0 Hi 8
N
4 .3HCl, MW: 423.77. 'H-NMR (200 MHz, d-DMSO) ppm: 3.0 (s, 6H), WO 2009/152868 PCT/EP2008/057908 40 6.98 (d, 2H), 7.83 (s, 1H), 8.14 (d, 2H), 8.23-8.39 (m, 4H), 8.74 (d, 2H), 9.65 (s, 1H). FT IR (ATR) cm: 1640, 1591, 1546, 1387, 1339, 1202, 1133, 812. Example 23: [6-(1H-imidazol-1-vl)-2-(4-trifluoromethoxyphenvl)lquinoline dihvdrochlo ride NNO ~~0 .2HCI I
CF
3 Analogously prepared as colorless solid (1.62 g; yield: 78 %) using 4-trifluoromethox phenylboronic acid in the Suzuky coupling. Crystallized from DCM/methanol, colorless solid, mp.: 260-262*C. C 19
H
12
F
3
N
3 0.2HCl, MW: 428.24. 'H-NMR (200 MHz, d 6 -DMSO) ppm: 7.59 (d, 2H), 8.03 (s, 1H), 8.23-8.63 (m, 7H), 9.92 (s, 1H). FT-IR (ATR) cn-: 1619, 1326, 1251, 1184, 1149, 849, 830. Example 24: r6-(IH-imidazol-1-vl)-2-(2-methyl-4-trifluoromethoxyphenyl)lquinoline di hydrochloride N N O N 0 .2HCI C
CF
3 Analogously prepared in 78 % yield, using (2-methyl-4-trifluoromethoxyphenyl)boronic acid in the Suzuky coupling. Crystallized from DCM/MeOH, slight grey powder melting at 269.7-274.5*C. C2 0
H
14
F
3
N
3 0.2HCl, MW:442.27. 1 H-NMR (200 MHz, d6-DMSO) ppm: 2.83 (s, 3H), 7.40 (d, IH), 7.77 (s, 1H), 8.80-8.57 (m, 8H), 9.60 (s, IH). FT-IR, (ATR) cm-1: 1638, 1616, 1270, 1224, 1149, 900, 885. Example 25: r6-(1H-imidazol-1-yl)-2-(4-methanesulfonlphenl)lquinoline dihydrochlo ride WO 2009/152868 PCT/EP2008/057908 41 N N N O
S.
.2HCI O' 6-(IH-imidazol-1-yl)-2-(trifluoromethane sulfonoxy)quinoline (1.06 g; 2.88 mmol) was dissolved in dry dioxane (35 mL), then LiCI (1.0 g, 2.88 mmol) and hexamethylditin (1 g, 2.88 mmol) and tretrakis-triphenylphosiphine palladium (25 mg, 0.02 mmol) were added under argon atmosphere. To the stirred suspension, 4-bromo-methanesulfonylbenzene (0.7 g, 3.0 mmol) dissolved in dry dioxane (3 mL) was added at r.t.. The resulting mixture was then refluxed for 48 hours, then cooled at r.t. and poured into water (100 mL). The result ing suspension was saturated with NaHCO 3 and the precipitate was extracted with AcOEt. The organic layer was washed with water then dried and concentrated to afford a brown solid. The product was dissolved in DCM/MeOH (9:1) and the hydrochloride was precipi tated by bubbling gaseous HCL. After crystallization from water the title product (600 mg, yield: 48%) was obtained as light-yellow solid melting at: 267.4-268.1*C.
C
19
H
15
N
3 0 2 S.2HCl, MW: 422.33. 'H-NMR (200 MHz, d 6 -DMSO) ppm: 3.32 (s, 3H) 7.83 (s, 1H), 8.14 (d, 2H), 8.23-8.66 (m, 7H), 9.58 (s, 111). FT-IR (ATR), cm 1 : 1600, 1508, 1298,1140,1090,963,820,774. 6-(1 H-imidazol- I -yl)-2-(trifluoromethane sulfonoxy)quinoline N NC N0oo N 0 CF 3 Sodium hydride (60% suspension in mineral oil, 8.7 g; 219.6 mmol) was added portion wise, under stirring at -3*C, under argon atmosphere, to a solution of 6-(IH-imidazol-lyl) 2-quinolinone hydrochloride (22 g; 87.8 mmol) in dry DMF (250 mL). Completed the ad ditions the reaction mixture was cooled at - 15*C, and Bis(trifluoromethylsulfonyl)phenyl amine (37.25 g, 104.25 mmol; RN: 37595-74-7, Aldrich) dissolved in dry DMF (100 mL) was added drop-wise, at such a rate to maintain the reaction temperature below -10 C. At the end of the addition the reaction temperature was allowed to rise to r.t., and the reaction mixture is stirred for further 2 hours. The reaction was then quenched in water (2.2 L), the precipitate was filtered, washed with water and then with hexane. The product was dis- WO 2009/152868 PCT/EP2008/057908 42 solved in DCM/methanol (9:1; 800 mL) and dried with Na 2
SO
4 . Concentration of the solu tion gave rise to crystallization of the titled product as a white solid which was filtered and dried (23.6 g; 77.8%). C 1 3
H
8
F
3
N
3 0 3 S, MW: 343.3; MS (ESI) m/z: 344 (M +1). H-NMR (200 MHz, d 6 -DMSO) ppm: 7.21 (s, 1H), 7.76 (d, 1H), 7.96 (s, 1H), 8.17 (d, 1H), 8.32 (dd, 1H), 8.49 (s, 2H), 8.76 (d, 1H). 6-(lH-imidazol- I -yi)-2-hydroxy-quinoline hydrochloride N ONN N OH HC 2-methoxy-6-(1H-imidazol-1-yl)-2-quinoline (26.4 g; 115.75 mmol) was suspended in 3N aqueous HCI (170 mL), the resulting reaction mixture was refluxed for 15 hours. The solu tion was then cooled to 0"C, the precipitated hydrochloride of the titled product was fil tered and washed with isopropanol, then dried to provide 22.0 g (75.8%) of the product as colourless crystals, m.p.: 348.7-352.5*C. C 12
H
9
N
3 0. HCl, MW: 247.73. 'H-NMR (200 MHz, D 2 0) ppm : 6.40 (d, 1H), 7.30 (d, 1H), 7.40 (dd, 2H), 7.48 (dd, 1H), 7.65 (d, 1H), 7.74 (d, IH), 9.60 (s, 1H). 6-(1H-imidazol- I -vl)-2-methoxy-quinoline Nt SN NN 0 6-bromo-2-methoxy-quinoline (19 g; 79.8 mmol; RN: 99455-05-7) was dissolved in dry DMF (100 mL), imidazole (5.7 g; 84 mmol), K 2 C0 3 (11.6g, 84 mmol), and CuI (1.lg, 4.2 mmol) were added at r.t. under stirring and in argon atmosphere. The resulting mixture was heated at 150'C for 48 hours. The reaction mixture was cooled at r.t. and poured into 2% (w/w) aqueous EDTA solution (600 mL), the resulting precipitate was filtered and washed with water, dried and then suspended in hexane/AcOEt. The resulting suspension was stirred for 10 min., filtered and the collected title product was dried, 14 g (yield 78%) of white crystals were obtained. C 13
H
11
N
3 0, MW: 225.25. MS (ESI) m/z: 226 (M +I). 'H- WO 2009/152868 PCT/EP2008/057908 43 NMR (200 MHz, CDC 3 ) ppm: 3.6 (s, 3H), 6.97 (s, 1H), 7.51 (s, 1H), 7.82 (d, IH), 8.10 (dd, 1H), 8.13 (d, 1H), 8.27 (s, 1H), 8.84 (d, 1H). 6-bromo-2-methoxy-quinoline Br N '_0 2-Chloro-6-bromo-quinoline (142.5 g, 0.6 mol; European Journal of Medicinal Chemistry, 35(10), 931-940; 2000; colourless crystals m.p.: 99.8-101.44C) was dissolved in methanol (700 mL), then sodium methoxide (43.9 g; 0.8 mmol) was added and the resulting reaction mixture was refluxed for 16 hours. The reaction mixture was cooled at r.t. and poured in ice-water (1.8 L), the titled product precipitated as a cream solid (133 g, 95%), melting at 157.9-161.1 0 C. CioH 8 BrNO 2 , MW: 238.09. MS (ESI) m/z: 239 (M+1). 'H-NMR (200 MHz, CDC 3 ) ppm: 4.06 (s, 3H), 6.91 (d, 1H), 7.64-7.75 (m, 2H), 7.88 (d, 2H). Example 26: [6-(2-methyl-1H-imidazol-1-yl)-2-(4-methoxyphenyl)lquinoline dihydrochlo ride NN N N .2HCI 0 6-(1H-2-methylimidazol-1-yl)-2-(trifluoromethane sulfonoxy)quinoline (3.77 g; 10.6 mmol) was dissolved in toluene (100 mL), then K 2 C0 3 (4.40 g, 31.8 mmol), tetrakis triphenylphosiphine palladium (0.733 g, 0.6 mmol), and 4-methoxyphenylboronic acid (1.74 g; 11.5 mmol) were added, at r.t., under stirring and in argon atmosphere. The result ing reaction mixture was heated at reflux for 2 hrs., then cooled at r.t. and poured in water. The organic layer was separated, the aqueous phase was extracted with DCM and the com bined organic layers were dried filtered and concentrated. The resulting solid was sus pended in isopropylether, stirred for 5 min. then filtered and dried. The solid was then dis solved in DCM/methanol (9:1, 30 mL) and gaseous HCl was bubbled until hydrochloride precipitation was complete. The hydrochloride was recrystallized from isopropanol/water to afford the titled product as colorless solid (720 mg; yield: 22%). C 20
H
17
N
3 0.2HC, MW: WO 2009/152868 PCT/EP2008/057908 44 388.38. m.p.: 230"C (dec). MS (ESI) m/z: 316 (M+1). 'H-NMR (200 MHz, d 6 -DMSO) ppm: 2.65 (s, 3H), 3.80 (s, 3H), 7.15 (d, 2H), 7.90-8.10 (m, 2H), 8.02-8.05 (m, 2H), 8.20 8.40 (m, 4H), 8.60 (d, 1H). FT-IR (ATR) cm-: 1598, 1510,1269,1170,1013, 835. Example 27: [6-(2-methyl-1H-imidazol-1-yl)-2-(2-methoxyphenyl)lquinoline dihydrochlo ride N 0 .2H01 Analogously prepared in 35% yield, using 2-methoxyphenylboronic acid in the Suzuky coupling. Crystallized from DCMlmethanol. C 2 0
H
17
N
3 0.2HCl, MW: 388.38. m.p.: 235*C (dec). 'H-NMR (400 MHz, d 6 -DMSO) ppm: 2.65 (s, 3H), 3.88 (s, 3H), 7.17 (t, 1H), 7.26 (d, 1H), 7.54 (d, 1H), 7.83-7.86 (m, 2H), 8.02-8.05 (m, 2H), 8.15 (d, 1H), 8.37 (d, iH), 8.41 (s, 1H), 8.61 (d, 1H). FT-IR (ATR) cm: 1641, 1599, 1491, 1429, 1256, 1171, 1013, 914, 761 Example 28: [6-(2-methyl-l H imidazol-l -y)-2-(3-furyl)]quinoline dihydrochloride N .2HCI 0 Analogously prepared in 69% yield, using 3-firylboronic acid in the Suzuky coupling. Crystallized from toluene, mp: 240.1-243.2 0 C. C 17
H
13
N
3 0.2HC, MW: 348.31. 'H-NMR (400 MHz, d-DMSO) ppm: 2.64 (s, 3H), 7.17 (t, 1H), 7.31 (s, 1H), 7.85 (d, 1H), 7.90 (m, 1H), 8.0 (dd, 1H), 8.03 (d, 1H), 8.12 (d, 1H), 8.28 -8.32 (m, 2H), 8.57 (d, 1H), 8.73 (s, 1H). FT-IR (ATR) cnf': 1647, 1620,1595,1499, 1368, 1280, 1170, 1152, 917, 860, 766. Example 29: [6-(2-methyl-1H imidazol-1-yl)-2-(phenyl)lquinoline dihydrochloride WO 2009/152868 PCT/EP2008/057908 45 N NN N .2HCI Analogously prepared in 79.5% yield, using phenylboronic acid in the Suzuky coupling. Crystallized from DCM/methanol, colorless solid mp.: 296-297*C . C 1 9 Hl 5
N
3 .2HCl, MW: 358.35 1 H-NMR (400 MHz, d 6 -DMSO) ppm: 2.64 (s, 3H), 7.60 (m, 3H), 7.86 (d, 1H), 8.01 (dd, IH), 8.03 (d, IH), 8.33 -8.38 (m, 5H), 8.63 (d, 1H). FT-IR (ATR) cm-: 1642, 1615, 1591, 1522, 1504, 1433, 1323, 1273, 1168, 921, 774, 756. 6-(I1H-2-methylimidazol-1-yl)-2-(trifluoromethane sulfonoxy)quinoline a :I0 ' -CF 3 6-(2-methyl-IH-imidazol-lyl)-2-quinolinone (5.14 g; 17.3 mmol) was dissolved in DMF (40 mL), then NaH (1.70 g, 60% dispersion in mineral oil, 43 mmol) was added portion wise, under argon flow, at -10 C. The resulting mixture was stirred at 0*C for 15 min. then cooled at -15*C, and bis(trifluoromethylsulfonyl)phenylamine (7.22 g, 20.2 mmol), dis solved in dry DMF (25 mL) is added drop-wise. The resulting mixture was stirred at -15*C for 30 min. then allowed to come to r.t. and stirred at that temperature for 1.5 hours. The reaction mixture is then poured in water (150 mL) the resulting precipitate is filtered and dried by co-evaporation with toluene. The product is than stirred with hexane few minutes, filtered and dried to provide the title product (5.3 g; yield: 88%). C 14
H
1 oF 3
N
3 0 3 S, MW: 357.3; MS (ESI) m/z: 358 (M +1). 'H-NMR (400 MHz, d 6 -DMSO) ppm: 2.4 (s, 3H), 7.0 (s, lH), 7.52 (s, IH), 7.79 (d, 1H), 8.0 (dd, IH), 8.15 (d, 1H), 8.31 (s, 1H), 8.82 (d, 1H). FT-IR (ATR) cm': 1666, 1511, 1414, 1207, 1130, 912, 862. 642-methyl- 1 H-imidazol- 1 -yl)-2-hydroxy-quinoline hydrochloride N HCI N OH WO 2009/152868 PCT/EP2008/057908 46 3-ethoxy-N-[4-(2-methyl-1H-imidazol-1-yl)phenyl]acrylamide (30 g; 110 mmol) was added at -5/-10*C to concentrated sulforic acid (120 mL) and the resulting mixture was stirred at r.t. overnight. The reaction mixture was quenched in ice/water (400 g), the pH was adjusted to pH=8 by adding K 2 C0 3 , the precipitate was filtered and then suspended in AcOEt/MeOH (9:1; 400 mL). The resulting suspension was stirred for 5 min., the inor ganic salts were filtered off, washed with AcOEt and the combined filtrate and washings, dried and concentrated. Column chromatography of the residue over silica gel (AcOEt/MeOH 9:1) afforded 15.3 g (62%) of an amorphous grey solid. This solid was dis solved at 60*C in 3 N HCl (150 mL), on cooling the hydrochloride crystallized, as a pale yellow solid which was filtered, washed with isopropanol and dried to afford the pure title product 13.8 g, (48%). C 13
H,
1
N
3 0.HCl, MW: 261.75; 'H-NMR (200 MHz, D 2 0) ppm : 2.44 (s, 3H), 6.40 (d, 1H), 7.30 (d, IH), 7.40 (dd, 2H), 7.48 (dd, 1H), 7.65 (d, 1H), 7.74 (d, 1H). 3-ethoxy-N-[4-(2-methvl-1H-imidazol-1-Vl)phenyllacrylamide N0 N 0 H 4-(2-methyl-IH-imidazol-1-yl)aniline (40.7 g, 232 mmol; RN: 74852-81-6, Maybridge, J. Med. Chem., 48(6), 1729-1744; 2005) was dissolved in dry pyridine (290 mL), 3 ethoxyacryloyl chloride (36.1 g, 268 mmol) was then added dropwise at 0*/-10 0 C. The re sulting mixture was stirred at 0*C for 2 hours and at r.t. overnight. The reaction mixture was quenched with 100 mL of water, and pyridine was distilled i.v., the residue was taken up with water and the pH was adjusted to pH=10, by adding K 2
CO
3 , the resulting suspen sion was extracted with AcOEt and concentrated. The resulting solid was stirred with hex ane and filtered to afford the title product (58 g; 92%). C 15
H
17
N
3 0 2 , MW: 271.32. Example 30: [6-(4-methyl-1H-imidazol-1-yl)-2-(phenyl)lquinoline dihydrochloride N .2HeI WO 2009/152868 PCT/EP2008/057908 47 6-(4-methyl-1H-imidazol-1-yl)-2-(trifluoromethane sulfonoxy)quinoline (1.0 g; 2.9 mmol) was dissolved in toluene (60 mL), then K 2 C0 3 (1.9 g, 9.35 mmol), palladium tetrakis thriphenylphosphine (0.40 g, 0.35 mmol), and phenylboronic acid (0.42, 3.9 mmol) were added under argon atmosphere. The resulting mixture was refluxed for 2 hours, then cooled at r.t. and quenched with water (100 mL). The organic phase was separated, the aqueous layer was extracted with toluene, and the combined organic phases were concen trated. The residue was taken up with dry toluene, concentrated again to small volume, then the hydrochloride was precipitated by bubbling gaseous HlI, to provide the title product as a light brown powder (380 mg, 36%) melting at: 285-289*C. C19HJ5N3.2HCl, MW: 358.35. 'H-NMR (200 MHz, d-DMSO) ppm: 2.30 (s, 3H), 7.60 (m, 3H), 7.86 (d, 2H), 8.01 (d, 1H), 8.03 (s, 1H), 8.33 -8.38 (m, 5H), 9.62 (s, 1H). Example 31: [6-(4-methyl-1H-imidazol-1-yl-2-(4-methoxvhenyl)]quinoline dihydrochlo ride N N N .2HCI O Analogously prepared in 75% yield, using 4-methoxyphenylboronic acid in the Suzuky coupling. Crystallized from DCMlmethanol, light yellow powder, m.p.: 276-278*C dec.
C
20
H
17
N
3 0.2HCl, MW: 388.38. 'H-NMR (400 MHz, d-DMSO) ppm: 2.31 (s, 3H), 3.81 (s, 3H), 7.00 (d, 2H), 7.47 (s, IH), 7.77 (d, 2H), 7.93 (t, 2H), 8.02 (s, 1H), 8.07 (d, 1H), 8.55 (d, IH), 8.97 (s, 1H). FT-IR (ATR), cmf: 1640,1596, 1511, 1368, 1298, 1261, 1184, 1015, 827. Example 32: r6-(4-methyl-1H-imidazol-1-yl)-2-(4-fluorophenyllkluinoline dihydrochlo ride Nzz: N 2NF .2HC F WO 2009/152868 PCT/EP2008/057908 48 Analogously prepared in 83% yield, using 4-fluorophenylboronic acid in the Suzuky cou pling. Crystallized from DCMimethanol, cream powder, m.p.: 264-268 0 C,
C
19
H
1 4
FN
3 .2HCl, MW: 376. 34. MS (ESI) m/z: 304 (M+I1). 'H-NMR (400 MHz, d DMSO) ppm: 2.27 (s, 3H), 7.16 (t, 2H), 7.40 (s, 1H), 7.73-7.70 (m, 2H), 7.84 (t, 2H), 7.86 (s, 1H), 7.96 (d, 1H), 8.46 (d, 1H), 8.90 (s, 1H). FT-IR (ATR), cm-1: 1615, 1597, 1537, 1510, 1458, 1369, 1329, 1249, 1170,1079,920,840,826. Example 33: [6-(4-methyl-1H-imidazol-1-yl)-2-(4-methylthiophenvl)]quinoline dihydro chloride N NN N .2HCI S Analogously prepared in 71% yield, using 4-methylthiophenylboronic acid in the Suzuky coupling. Crystallized from DCM/methanol, light orange powder, m.p.: 294-296*C.
C
20
H
17
N
3 S.2HCI, MW: 404.34. MS (ESI) m/z: 332 (M+1). 'H-NMR (400 MHz, d6 DMSO) ppm: 2.38 (s, 3H), 2.53 (s, 3H), 7.43 (d, 2H), 8.07-8.11 (m, 2H), 8.22-8.28 (m, 4H), 8.38 (s, 1H), 8.53 (d, 1H), 9.63 (s, lH). FT-IR (ATR), cm-1: 1588, 1545, 1418, 1361, 1192, 1095, 1063, 976, 938, 804, 797. 6- 4-methyl-IH-imidazol-1-l)-2-(trifluoromethane sulfonoxy)quinoline N 0 CF 3 6-(4-methyl-IH-imidazol-lyl)-2-quinolinone (8.53 g; 28.7 mmol) was dissolved in DMF (80 mL), then NaH (3.4 g, 60% dispersion in mineral oil, 85.4 mmol) was added portion wise, under argon, at -7 *C. The resulting mixture was stirred at 0'C for 15 min. then cooled at -15*C, and bis(trifluoromethylsulfonyl)phenylamine (13.3 g, 40.1 mmol), dis solved in dry DMF (35 mL) was added drop-wise. The resulting mixture was stirred at 5*C for 20 min. then allowed to come to r.t. and stirred at that temperature for 1 hour. The reaction mixture is then poured in water (300 mL), the resulting precipitate is filtered and dried by co-evaporation with DCM. The product is then stirred with hexane few minutes, WO 2009/152868 PCT/EP2008/057908 49 filtered and dried to provide the title product as brown crystals, (8.0 g; yield: 79 %), m.p.: 150.4-152.14C. C 14 HioF 3
N
3 0 3 S, MW: 357.3; MS (ESI) m/z: 358 (M +1). 6-(2-methyl-1H-imidazol-1-yl)-2-hydroxy-quinoline hydrochloride N HCI N OH 3-ethoxy-N-[4-(4-methyl-1H-imidazol-1-yl)phenyl]acrylamide (18.0 g; 6.8 mmol) was added at -5/-10 0 C to concentrated sulforic acid (100 mL) and the resulting mixture was stirred at r.t. for 25 hrs.. The reaction mixture was quenched in ice/water (400 g), and stirred for further 30 min., then the pH was adjusted to pH=8 by adding K 2 C0 3 . The pre cipitate was extracted using AcOEt/MeOH (9:1; 4x150 mL), the combined organic extracts were dried and concentrated. The residue was taken up with isopropanol (70 mL) and aqueous HCI (6 N, 15 mL) was added at +5*C under stirring, the resulting precipitate was filtered, washed with isopropanol, then with isopropyl ether, and dried to afford 8.53g (44%) of the title compounds as a brown solid, m.p.: 274-277*C. 3-ethoxy-N-[4-(4-methyl-i H-imidazol-1 -yllphenyllacrylamide N NaN 0 H 4-(4-methyl-1H-imidazol-1-yl)aniline (15 g, 138 minmol) was dissolved in dry pyridine (80 mL), freshly distilled 3-ethoxyacryloyl chloride (19 g, 140 mmol) was then added drop wise at 5*/0*C. The resulting mixture was stirred at 0*C for I hours and at r.t. overnight. The reaction mixture was quenched with water (500 mL), the pH was adjusted to pH=10, by adding K 2 C0 3 and the resulting solid was filtered, washed with water and dried, to pro vide the title product as slight orange powder (18.6 g; 75%), m.p.: 214-216 0 C. Cs1 5 141N 3 02 MW: 271.32. 4-(4-methyl-I H-imidazol- 1 -yl)aniline WO 2009/152868 PCT/EP2008/057908 50 N NH 4-(4-methyl-lH-imidazol-1-yl)nitrobenzene (22.5 g; 0.87 mmol) is dissolved in abs. etha nol (250 mL), then SnCI 2 .2H 2 0 (125 g; 0.55 mol) is added portion-wise, on cooling at 0 0 C. The resulting mixture is stirred at r.t. for 2 hours and heated at reflux overnight. The reac tion mixture is then cooled at r.t. and the pH is adjusted to 12, by adding 30% KOH (500 mL), then KOH pellets under stirring. The resulting suspension is filtered and the cake is washed with ethanol, the combined filtrate and washings are concentrated and the residue is extracted with DCM. Concentration of the combined organic extracts afforded the title product as a slight brown solid (15.3 g; 80%), m.p.: 122-125*C. C 10
H
1 iN 3 , MW 173,22. 4-(4-methyl- I H-imidazol- I -yl)nitrobenzene N 0 4-fluoronitrobenzene (32.3 g; 0.229 mol) and 4-methyl-1H1-imidazole (25 g; 0.3 mol) are mixed at r.t., to this stirred mixture K 2 C0 3 (44 g; 0.3 mol) is added. The reaction mixture is then heated at 120*C overnight, then cooled at r.t. and poured in water (2L), the resulting suspension is filtered and washed with water. The obtained solid is dried at 60*C and re crystallized from ethyl acetate (600 mL), to provide the title compound as a yellow solid (22.5 g; 48.3%). The regioisomer, 4-(5-methyl-IH-imidazol-lyl)nitrobenzene remains in the crystallization mother liquor along with a certain amount of the titled product (TLC: hexane/AcOEt 3:2). C 10
H
9
N
3 0 2 , MW 203.2. Pharmacological Evaluation of the Compounds of the Invention Binding study towards I2 imidazoline receptor subtype in rat brain. Experiments were performed according to the procedure of Lione LA et al.,1998 (Eur. J. Pharmacol., 353:123-135). Male Wistar rats (240-300 g, Harlan, Italy) were sacrificed by decapitation. Whole brains were immediately removed on ice and homogenised in 10 vol umes of buffered sucrose (0.32M in 50mM Tris-HCI, pH 7.4 at 4 0 C) using a motor driven Teflon-glass homogeniser. The homogenate was centrifuged at 1000 X g for 10 min at WO 2009/152868 PCT/EP2008/057908 51 4"C. The resultant supernatants were pooled and centrifuged at 32000 X g for 20 min at 4 0 C. The supernatants were discarded and each pellet suspended in 10 volumes of assay buffer (50 mM Tris-HCl, 1 mM MgCI2, pH 7.4 at 4C) and spun at 32000 X g for 20 min at 4 0 C. The pellets were washed twice by repeated centrifugation at 32000 X g for 20 min at 4*C. The final pellets were stored at -80'C until use. Prior to radioligand binding stud ies, membrane pellets were thawed and washed a further 4 times by re-suspension in 10 volumes of assay buffer (as above) and repeated centrifugation to remove any possible en dogenous inhibitors of binding. The protein content of the membrane preparations was de termined, using bovine serum albumin as the standard (Bradford M, 1976, Anal. Biochem., 72 :248-254). For routine procedures (competition binding assays) 250 pl of membranes suspension (2 mg protein /ml) were incubated with [3H]-2BFI (2.5 x 10-9 M; GE Health care, 66Ci/immol), in the absence or presence of various concentration of test compounds. Non specific binding was determined in the presence of 10-5 M BU224 (Tocris Biosci ence). The incubation, in a final volume of Iml, was performed in polystyrene multiwell 24, started adding membranes suspension and was carried out for 90 min at 25*C. With the exception of total binding and non specific binding, all concentration points were per formed in duplicate. Compounds were tested in 3-5 different concentrations, ranging from 10-10 M to 10-5 M final concentration. The affinity expressed as IC50 value (concentration which has a 50% displacing potency) was calculated by linear regression (log pM concen tration of test compound vs. % specific residual binding B/Bo). Monoaminooxidase (MAO) activity assay. Inhibitory activity of compounds was evaluated by a homogeneous luminescent method, the MAO-GloTM Assay (Promega), measuring the monoamine oxidase activity (MAOs) from recombinant source (microsomes from baculovirus infected insect cells, Sigma). Ex periments were performed according to the Supplier's procedure, incubating human re combinant MAO-A or MAO-B with a luminogenic substrate, a derivative of beetle luci ferin ((4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid). MAOs converts this luciferin derivative to methyl ester luciferin and only compounds that inter fere with the ability of the enzyme to use the pro-luminescent substrate will cause changes in the resulting luminescent signal. The MAO-GloTM Assay was performed in two steps: Stepl. The MAO reaction: MAO substrate was incubated with MAO-A or MAO-B (1 WO 2009/152868 PCT/EP2008/057908 52 pg/sample ) in the absence (Total activity) or presence (modulated activity) of test com pounds. Total activity was determined in the presence the appropriate solvent. The sub strate concentrations for MAO-A and MAO-B correspond to their apparent Km (40 gM and 4 riM, respectively). Reaction started adding the enzyme solution and samples were incubated for 60 min at room temperature. For negative control reaction, samples of MAO reaction buffer (100 mM Hepes, 5% glycerol, pH 7.5) indeed the test compound were in cluded . For MAO-B activity assay, MAO reaction buffer contain 10% DMSO, in order to increase enzymatic activity. Step2. Luciferin Detection: The methyl ester luciferin, produced in step I by the action of MAO on the MAO substrate, reacts with esterase and luciferase (detection reagent) to gen erate light. At the end of incubation 50 p] of Luciferin Detection reagent were added to each well, plate was incubated at room temperature for 20 min , then luminescent signal was detected by luminometer (integration time 0.25-1 sec per well) . Values were dis played as relative light unit (RLU). Net MAO-dependent luminescence (net RLU ) were calculated by subtracting the average luminescence of the negative control reaction without MAO enzyme. A reduction of net signal in the presence of test compound, with respect to total activity, reflect its effect on MAOs activity. All compounds were initially tested at 10 5 M final concentration, then inhibition curves for active compounds, spanning in at least two order of magnitude concentrations, were performed. A percentage of inhibition for each concentration tested were calculated and the IC 5 0 value was estimated by linear re gression. Table 2: 12 Imidazoline Receptor Binding & Monoaminooxidase (MAO) activity as say. Compound 1PH]2-BFI binding MAO A activity MAO B activity
IC
50 (pM) IC 50 (pM) IC 50 (pM) Example 1 0,68 0,22 > 10 Example 2 2,40 > 10 > 10 Example 4 0,48 2,06 > 10 Example 5 1,18 >10 > 10 Example 6 1,16 >10 > 10 Example 7 2,18 >10 >10 Example 9 1,04 >10 > 10 Examp e 13 1.34 10 >10 WO 2009/152868 PCT/EP2008/057908 53 Example 14 0,61 0,35 > 10 Example 15 0,50 > 10 >10 Example 16 0,19 > 10 > 10 Example 17 0.42 1,13 10 Example 18 1,90 0,67 > 10 Example 19 3,16 >10 > 10 Example 20 1,19 0,25 >10 Example 21 0,24 >10 >10 Example 22 3,78 2,09 1,49 Example 23 0,82 0,15 > 10 Example 24 1,14 0,28 >10 Example 25 0,85 0,45 > 10 Agmatine >10 > 100 > 100 2-BFI 0,007 > I > 1 Idazoxan 0,011 > 1 > 1 Clorgyline 1,53 0,027 14,30 Deprenyl 2,31 19,10 0,48 These in vitro data highlights how within the group of compounds of formula (I) it is pos sible by changing the substitution pattern to modulate 12 Receptor, MAO-A and MAO-B enzymes activity. For instance, introduction of methyl onto imidazol ring allows to retain activity towards 12 Receptor while losing MAO inhibitory activity (see for instance com pounds at examples 2 and 5 vs. example 1), same effect is obtained with an appropriate substitution both at the imidazol and at the phenyl in position 2 (see for instance com pounds at examples 6 and 9 vs. example 1). Appropriate substitution at the phenyl in posi tion 2 can also modulate MAO-A vs. MAO-B activity (see for instance compound at ex amples 22 vs. example 17). Accordingly, compounds of the invention can be either selec tive I2 Receptor agonists, endowed with striking in vitro potencies, or balanced 12 Recep tor agonists / MAO-A vs. MAO-B inhibitors. Tail suspension test in mice To evaluate novel antidepressants compounds several animal models have been developed. Among them, the tail suspension test is a simple, fast and convenient model in which many antidepressants reduce the immobility time, indicating that this parameter can be used as an index of antidepressant activity. The antidepressant effect of representative examples of compounds of formula (1) has been evaluated according to the procedure below. The im mobility was induced according to the procedure of Steru et al. (1985). CDI Mice (Harlan, Italy) were individually suspended 75 cm above the top with an adhesive tape placed 1 cm WO 2009/152868 PCT/EP2008/057908 54 from the tip of the tail. Immobility duration was recorded for 5 min. Mice were considered immobile only when they hung passively and completely motionless. Compounds were given orally, 30 min before the test at doses ranging between 0,3 and 30 mg/kg. Data col lected were expressed as mean percent effect (MPE), which represents the % of inhibition in immobility time between the animals treated with representative compounds of formula (1) and the controls that received only the vehicle. From the MPE data, the dose yielding a reduction of 50% (ED 5 o) has been calculated. Table 3: Compound Dose MPE ED 50 mg/Kg; mg/Kg; OS OS 0,3 35 1 38 Example 1 3 40 4,8 10 66 30 84 3 17 Example 2 10 77 7,1 30 83 3 41 Example 5 10 61 4,9 30 91 3 41 Example 16 10 66 4,6 30 100 3 36 Example 21 10 72 4,9 30 89 3 23 Example 25 10 54 8,7 30 40 Commercially available Reference ED 50 antidepressant drugs mg/Kg; SC Reboxetine Millan MJ et al., 4,2 2001 JPET, 298(2):581 591 Citalopram Millan MJ et al., 8,8 2001 JPET, 298(2):581 591 Venlafaxine Millan MJ et al., 11,7 WO 2009/152868 PCT/EP2008/057908 55 2001 JPET, 298(2):581 591 Mice treated with representative compounds of formula (1) exhibited dose-dependent anti depressant-like activities in the "Tail Suspension Test" as compared with standard refer ence drugs. Table 4: Compound Dose MPE ED 50 mg/Kg; OS mg/Kg; OS Example 1 3 43 10 54 5,1 30 97 Example 1 3 7 + Idazoxan 0,3 mg/Kg; IP 10 39 NC 30 43 NC: not computable As showed in table 4, the antidepressant-like effect of -Example 1- was blocked (dose response shifted to the right) by the presence of a commercially available antagonist of imidazoline (12) receptors (0,3 mg/Kg Idazoxan). This effect was fully in agreement with "in vitro" data showed in table 2 where representative compounds object of the present in vention were able to inhibit the binding of [ 3 H]2-BFI with ICso in the low micromolar range. This means that the behavioural antidepressant-like effect of representative com pounds of formula (I) could be mediated, at least in part, by their interaction with imida zoline (12) receptors. CFA model of inflammatory pain in rats: effect of a representative compound of formula (I) in potentiating the effect of a low dose of morphine The effects of compounds of formula (1) were evaluated in an animal model of chronic in flammatory pain. In particular, it has been investigated their potential ability to increase the absolute analgesic power of a low dose of morphine. Recently, it has been shown that the use of Complete Freund's Adjuvant (CFA; Mycobacterium tuberculosis) as a triggering agent for the inflammatory response, along with the use of an appropriate protocol, is a suitable model of chronic pain. CFA-induced prolonged inflammation has been used ex tensively in studies of behavioural pain response (K. Walker, Mol Med Today, 1999, WO 2009/152868 PCT/EP2008/057908 56 5,319-321), since it has been considered also suitable for studying involvement of neuronal plasticity in chronic pain (R. Sharif Naeini, Eur. J. Neuroscience, 2005, 22, 8, 2005 2015). Experiments are performed as described in the literature (C.J. Woolf, Br. J. of Pharmacology, 1997, 121, 417-424); 6 rats were used for each group, each product was tested with a single oral dose of 1,5 mg/Kg in the presence or absence of a fixed low dose of morphine (0,5 mg/Kg; subcutaneously). Compounds of formula (I) were administered 24 hours after the interplantar challenge, and the analgesic activity was measured starting from the 24 hours following the challenge. In Table 5, results obtained in the CFA model, for a representative compound of formula (I), co-administered with a low dose of mor phine, are listed in comparison to the same dose of morphine administered alone. Analge sic effect was assessed using the Randall-Selitto model. Results are reported as mean per cent effect (MPE) which represents the difference (%) in pain threshold between the ani mals treated with the drugs and the controls that received only the vehicle (reduction of the nociceptive effect, due to paw loading with increasing weight, in comparison to controls which received CFA treatment). 100% protection means that the animals treated with the compounds and CFA can tolerate the same stimulus (weight) as the control animal which has not received CFA treatment. Table 5: Compound Dose MPE % MPE % MPE % mg/Kg; 2h effect 3h effect 4h effect OS Example 1 1,5 17,19 6,61 2,46 Morphine 0,5 - 42,88 - 30,49 - 15,04 mg/Kg; SC Example 1 1,5 98,30 + 129 90,73 + 198 82,46 + 448 + Morphine 0,5 mg/Kg; SC The representative compound of formula (I) - Example 1 - administered orally at a dose not able to induce analgesic-like effects by its own, demonstrated a pronounced sparing ef fect when administered as add-on with a low dose of morphine. Moreover, the increase in potency due to the treatment was linked to an outstanding and surprising increase in the WO 2009/152868 PCT/EP2008/057908 57 duration of the analgesic effect. The absolute analgesic effect of the add-on treatment was 2.29, 2.98 and 5.48 times more efficacious than morphine alone 2, 3 and 4 hours after drug administration, respectively. The effect at 4 hours is particularly relevant, since at this time the animals treated with morphine alone showed a very minor reduction of hyperalgesia, while the animal co-administered with morphine and the compound at Example 1, were still almost completely protected from hyperalgesia. Pharmaceutical compositions Compounds of formula I, their salts and solvates thereof, can be used in the manufacture of a suitable medication for the therapeutic treatment of Depression and Anxiety as above specified, for the pharmacological treatment of Parkinson's disease, for the pharmacologi cal treatment of the withdrawal symptoms for alcohol, tobacco and narcotics abuse, includ ing Cocaine abuse, and to avoid remission episodes. In addition, compounds of formula (I), their salts and solvates thereof, can be used alone or in combination with morphine or other opioid drugs in the manufacture of a suitable medication for potentiation of the opioid pharmacological action and/or for the dosage reduction of the opioid drug. Finally, com pounds of formula (I), their salts and solvates thereof, can be used in the manufacture of a suitable medication for the treatment of tolerance and dependence due to opioid drugs use. The compounds of the present invention may be administered orally or parenterally. The term parenteral used herein includes intravenous, intramuscular, subcutaneous. For all methods of treatment herein discussed for compounds of formula (I), its salt or solvate, the daily oral dosage regimen will preferably be from about 0.1 to about 20 mg/Kg of total body weight. It will also be recognised by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I) will be determined by the nature and extent of the condition being treated. This invention also relates to a composi tion suitable for the treatment of the above diseases, containing a pharmaceutically effec tive amount of a compound of formula (I), its salts or solvates, and a pharmaceutically ac ceptable carrier or diluent. In order to use a compound of formula (I) in therapy, it will normally be formulated into a dosage form in accordance with conventional methods of pharmacy and current guidelines and relevant good laboratory and manufacturing prac tices. The preferred route of administration for the compounds of the invention is oral. The compounds of the invention can be formulated in a wide variety of oral dosage forms, such WO 2009/152868 PCT/EP2008/057908 58 as capsules, tablets, pills, powders and dispersible granules. Suitable carriers can be one or more substances which may also act as diluents, flavouring agents, solubilizer, lubricants, suspending agents, binders. Suitable carriers include but are not limited to magnesium car bonate, magnesium stearate, talc, lactose, pectin, dextrin, starch, methylcellulose, sodium carboxymethyl cellulose, cocoa butter and the like. Techniques used to prepare oral formu lations are the conventional mixing, granulation and compression or capsules filling. Other forms suitable for oral administration include emulsions, syrups and aqueous solutions. Emulsions can be prepared using emulsifying agents for example lecithin, propylene glycol or sorbitan monooleate. Aqueous solutions can be prepared by dissolving the active com ponent in water and adding suitable colorants, flavours, stabilising agents. The compounds of the present invention may be formulated for parenteral administration (e.g., by injection or by continuous infusion) as a composition with suitable carriers includ ing aqueous vehicles solutions (i.e.: saline, dextrose) or and/or oily emulsions. The drug product may be presented in unit dose forms, for example in ampoules or pre-filled sy ringes.

权利要求:
Claims (12)
[1] 1. Compounds of formula (I) their pharmaceutically acceptable salts and/or solvates, and corresponding pharmaceutical formulations, for use in the pharmacological treatment of Depression including Major depressive disorder, Dysthymic disorder, Type II bipolar disorder, manic-depression, Anxiety disorders and panic disorder: Compounds of formula (I): R1 R1 W wherein: - X is independently selected from -CH group or a nitrogen atom (-N); - W is independently selected from an aryl group, or an heteroaryl group of formula II: Q Y Heteroaryl group of Formula H: - when W is an aryl group, it is intended an unsubstituted or substituted phenyl, with one or more substituents independently selected from halogen (-F, -Cl, -Br), trifluoromethyl ( CF 3 ), alkyl (-R 2 ), hydroxyl (-OH), alkoxy (-OR 2 ), trifluoromethoxy (-OCF 3 ), cyano (-CN), carboxamido (-CONHR 3 or -NHCOR 3 or -CONR 2 R 3 or -NR 2 COR 3 ), carbonyl (-CO-R 3 ), alkylthio or thiol (-SR 3 ), sulfinyl (-SOR 3 ) and sulfonyl (-SO 2 R 3 ) being R 2 and R 3 as de fined below; - when W is an heteroaryl group of formula II, it is a benzocondensed -5 or -6 membered heterocycle, wherein: - Z and Y are independently selected from: an oxygen atom (-0-), a sulphur atom (-S-), or the groups: -CHR 3 -, -CR 3 =, -NH-, -N=; - Q is independently selected from the groups: -CHR 3 -, - CH=, -CR3=, -CHR 3 -CH 2 -: provided that the combination of Y, Z, Q groups give rise to: 1,3-benzodioxole, benzofu ran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-di hydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [1,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan); - R 1 is independently selected from hydrogen (-H) or CI-C 4 alkyl or hydroxymethyl (- WO 2009/152868 PCT/EP2008/057908 60 CH 2 OH), aminomethyl (-CH 2 NH 2 ), alkylaminomethyl [-CH 2 NH(R 2 )), di-alkylaminome thyl [-CH 2 N(R 2 ) 2 ], trifluoromethyl (-CF3); the C 1 -C 4 alkyl group is a linear or branched saturated or unsaturated C 1 -C 4 hydrocarbon chain; provided that in compounds of formula (I) not more than two R 1 groups substituting the imidazole ring, are simultaneously CI-C 4 alkyl or trifluoromethyl (-CF 3 ) and only one Ri group is hydroxymethyl (-CH2OH), ami nomethyl (-CH 2 NH 2 ) alkylaminomethyl [-CH 2 NH(R 2 )], di-alkylaminomethyl [ CH2N(R2)2];, - R2 is a Ci-C 6 alkyl chain; herein the C 1 -C 6 alkyl chain is intended as above defined for C 1 -C 4 but optionally substituted with an aryl, aryl being herein as defined above; - R3 is independently selected from hydrogen, CI-C 4 alkyl as defined above for RI; including all the possible tautomers of compounds of formula (I).
[2] 2. The compounds of formula (I) as defined in claim 1, wherein W is an heteroaryl group independently selected from the following penta- or hexa-atomic heterocycles: 2 furyl, 3-furyl, 2-thienyl, 3-thienyl, pyrrole-2-yl, pyrrole-3-yl, pyridine-4-yl, pyridine-3-yl, pyrimidin-4-yl; the heterocyclic ring being optionally substituted with one or two substitu ents independently selected from: RI, alkoxy (-OR 2 ) or hydroxy (-OH), wherein R 1 and R2 are as defined in claim 1.
[3] 3. The compounds of formula (I), as defined in claim 2, their pharmaceutically accept able salts and/or solvates, and corresponding pharmaceutical formulations, for use in the pharmacological treatment of Depression including Major depressive disorder, Dysthymic disorder, Type II bipolar disorder, manic-depression, Anxiety disorders and panic disorder.
[4] 4. A compound of formula (I) as defined in claim 1, wherein the substituent Ri at the imidazole ring is methyl, said compound being selected from the group consisting of: [6 (2-methyl-iH-imidazol-1-yl)-2-phenyl]quinazoline; [6-(2-methyl-1H-imidazol-1-yl)-2-(4 methoxyphenyl)]quinazoline; [6-(4-methyl-1H-imidazol-1-yl)-2-phenyl]quinazoline; [6-(5 methyl-1H-imidazol-1-yl)-2-phenyllquinazoline; [6-(4-methyl-IH-imidazol-1-yl)-2-(4-me thoxyphenyl)]quinazoline; [6-(4-methyl-1H-imidazol-1-yl)-2-(2-methoxyphenyl)]quinazo line; [6-(4-methyl-IH-imidazol-1-yl)-2-(3-methoxyphenyl)]quinazoline: [6-(4-1H-imida zol-1-yl)-2-(1,3-benzodioxol-5-yl)]quinazoline; [6-(4-methyl-1H-imidazol-1-yl)-2-(4-fluo- WO 2009/152868 PCT/EP2008/057908 61 rophenyl)]quinazoline; [6-(4-methyl-1H-imidazol-1-yl)-2-(4-metanesulfonylphenyl)]qui nazoline; [6-(IH-imidazol-1-yl)-2-(4-methoxyphenyl)]quinoline; [6-(1H-imidazol-1-yl)-2 (2-methoxyphenyl)]quinoline; [6-(1H-imidazol-1-yl)-2-(1,3-benzodioxol-5-yl)lquinoline; [6-(1H-imidazol-1-yl)-2-(4-fluorophenyl)]quinoline; [6-(1H-imidazol-1-yl)-2-(4-dimethyl aminophenyl)]quinoline; [6-(1H-imidazol-1-yl)-2-(4-trifluoromethoxyphenyl)]quinoline; [6-(IH-imidazol-1-yl)-2-(2-methyl-4-trifluoromethoxyphenyl)]quinoline; [6-(1H-imidazol 1-yl)-2-(4-dimethylaminophenyl)]quinoline; [6-(1H-imidazol-1-yl)-2-(4-methansulfonyl phenyl)]quinoline; [6-(2-methyl-IH-imidazol-I-yl)-2-(4-methoxyphenyl)]quinoline; [6-(2 methyl-iH-imidazol-1-yl)-2-(2-methoxyphenyl)]quinoline; [6-(4-methyl-1H-imidazol-1 yl)-2-phenyl)]quinoline; [6-(4-methyl-IH-imidazol-1-yl)-2-(4-methoxyphenyl)]quinoline; [6-(4-methyl-1H-imidazol-1-yl)-2-(4-fluorophenyl)]quinoline; and [6-(4-methyl-1H-imida zol-I -yl)-2-(4-methylthiophenyl)]quinoline.
[5] 5. The compounds of formula (I) according to any of claims from I to 4, their pharma ceutically acceptable salts and/or solvates, and corresponding pharmaceutical formulations, for use in the pharmacological treatment of Parkinson's disease.
[6] 6. The compounds of formula (I) according to any of claims from I to 4, their pharma ceutically acceptable salts and/or solvates, and corresponding pharmaceutical formulations, for use in the pharmacological treatment of the withdrawal symptoms and to avoid remis sion episodes for alcohol, tobacco and narcotics abuse including Cocaine abuse.
[7] 7. The compounds of formula (1), according to any of claims from 1 to 4, their pharma ceutically acceptable salts and/or solvates, and corresponding pharmaceutical formulations, alone or in combination with morphine or other opioid drugs for use in the enhancement of the opioid pharmacological action and/or for the dosage reduction of the opioid drug.
[8] 8. Use of the compounds of formula (I), according to any of claims from 1 to 4, their pharmaceutically acceptable salts and/or solvates, and corresponding pharmaceutical for mulations, for use in the pharmacological treatment of tolerance and dependence due to opioid drugs use. WO 2009/152868 PCT/EP2008/057908 62
[9] 9. Process for preparing a compound of formula (I) where X is a nitrogen atom (-N), according to claims from I to 4, which consists in reacting a compound of formula (VIII) with a compound of formula (IX) or (IXa): HN OMe R1 RI HCI N_ R1 N (IX) N N H 2 1) Cyclization RN 2) Oxidation Compound of fonnula VIII HN We Compound of fonnula I R1 .HCI R NNR1 R1 R N N (Xa) R1 Ri ~- NH 2 (Ia R1 N NH 2 1) Cyclization z Compound of formula VIII 2) Oxidation Compound of fonnula I where the condensation and cyclization reaction of bisamines of formula (VIII), with Pin ner salts of formula (IX), or of formula (IXa), being RI, R 3 , Y, Z and Q are as reported for compounds of formula (I), is obtained by heating the reaction mixture in an alcoholic sol vent, preferably methanol, ethanol or propanol at reflux temperature; the formed interme diate amidine is then cyclized to the corresponding dihydroquinazoline on heating in acetic acid; the oxidation of the obtained dihydroquinazoline intermediate to the corresponding compound of formula (I) is obtained using MnO2 in an inert organic solvent such as di chloromethane; Pinner salts of formula (IX) and (IXa) are prepared by bubbling anhydrous hydrochloric acid in the alcoholic solution of the corresponding nitrile, at a temperature be tween -20" and 0*C, then after evaporation of the solvent they are crystallised from a dial kyl ether, preferably tertbutylmethylether.
[10] 10. Process for preparing a compound of formula (I) where X is a -CH group, according to claims from I to 4, which consists in reacting a compound of formula (XII) with a com pound of formula (XIII) or (XIIa): WO 2009/152868 PCT/EP2008/057908 63 RI R1 RI- N N NRi N N R1OTf (HO)B R N W Compound of Formula XII (XaII) Compound of Formula I z RI R1 Ri N10 -' R1"Z N N Ri A (HO) 2 B Ri Z R1 N OVf N W Compound of Formula XI (XIIla) Compound of Formula I OTf- trifluoromethansulfonate wherein RI, R 3 , W, Z, Q and Y are as defined for compounds of formula (I); wherein the reaction of a compound of formula (XII) with the boronate of formula (XIII) or (XIIIa) is carried out in an inert organic solvent, preferably selected from toluene, dimethoxyethane or tetrahydrofurane, in the presence of a base such as potassium carbonate or caesium car bonate and under catalysis of palladium, preferably selected from Palladium tetra kistriphenylphosphine or Palladium-dichlorobis(triphenylphosphine), Tris(dibenzylidene acetone)dipalladium, [2,2'-bis(diphenylphosphino)-1,1'-binaphtyl]palladium or [1,3-bis (diphenylphosphino propane] palladium.
[11] 11. Process for preparing a compound of formula (XII) where R is as defined for com pounds of formula (I), starting from 2-methoxy-6-bromoquinoline: R1 N_ R1 Ri N N Ri N N RI ~ARI A A N 0 N OTf H Compound of Formula XIV Compound of Formula XII OTf= trifluoromethansulfonate R1 R Ri N N N R N Br N N N o0_ __ Compound of Formula XV Compound of Formula XVI where the preparation of a compound of formula XII from a compound of formula XIV is WO 2009/152868 PCT/EP2008/057908 64 carried out in pyridine using trifluoromethanesulfonic anhydride or trifluoromethanesul fonyl chloride at temperatures between 0* and -10*C, or using an organic base, preferably triethylamine or diisopropylethylanine, in an inert organic solvent, preferably dichloro methane, or using bis-trifluoromethylanilide in dimethylformamide, in the presence of so dium or potassium or calcium hydride; conversion of a compound of formula (XV) into a compound of formula (XIV) is achieved using hydrochloric or hydrobromic acid, at tem peratures ranging from 25*C to reflux temperature, or using BBr 3 in an inert solvent such as dichloromethane; compounds of formula (XV) are in turn prepared reacting 6-bromo-2 methoxyquinoline, formula XVI, with imidazole derivatives of formula (IV), which can be used as free bases or corresponding alkaline metal salts, preferably sodium, lithium or po tassium salts; the reaction is carried out in the presence of a suitable catalyst and a base, in a solvent, preferably selected from dimethylformamide, dimethylsulfoxide, acetonitrile, N metylpyrrolidone, dimethoxyethane, tetrahydrofurane, toluene or xylene, at a temperature ranging from 50 *C to reflux temperature; as catalyst a copper catalyst such as Cul, a mix ture of Cu/CuO or Cu(OTf)2.benzene complex can be used, optionally in the presence of suitable ligand such as 8-hydroxyquinoline, 1,10-phenantroline, dimethylethylenediamine, dibenzylidene acetone; said base being preferably selected from potassium carbonate, cac sium carbonate, triethylammonium carbonate; alternatively, palladium can be used as cata lyst for this reaction as Binap [2,2'-bis(diphenylphosphino)-1,I'-binaphtyl] or Dppf [1,3 bis(diphenylphosphino propane] palladium soluble catalysts, in dimethylformamide as sol vent, and potassium tert-butylate as base, under conventional or microwave heating.
[12] 12. Process for preparing a compound of formula (I), where X is a -CH group, according to claims from I to 4, which consists in reacting a compound of formula (XII) with a com pound of formula (XIIfb) or (XllIc): WO 2009/152868 PCT/EP2008/057908 65 R1 R1 I *ISn-Sn(Me) R1 RI R1 OVf B R1 N'-W >R3 Compound of Formula XII (Xllfb) Compound of Formula I RI N (Me),Sn-Sn(Me), R N R1 Ri N O Bf Zr- RI SOTf BQ N W Compound of Formula X1I (XIlic) Compound of Formula I oTfN trifluoNmethansuWfonate where the reaction is carried out with bis-(trimethyl)tin or bis-(tributyl)tin in the presence of a palladium catalyst, preferably selected from Tetrakis(triphenylphosphine)palladium, Tris(dibenzylideneacetone)dipalladium, Palladium-dichlorobis(triphenylphosphine) in the presence of lithium chloride or potassium fluoride in a suitable solvent, preferably selected from dioxane, tetrahydrofurane, dimethoxyethane, dimethylformamide or toluene.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2008357946B2|2013-06-20|6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands

---

AU2003245442B2|2009-02-05|2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections

---

KR100417779B1|2004-02-05|Substituted Benzimidazoles and Their Use as PARP Inhibitors

---

US5424450A|1995-06-13|Angiotensin II receptor blocking imidazolinone derivatives

---

US6958349B2|2005-10-25|Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

---

IL169720A|2011-08-31|Benzimidazole derivatives and pharmaceutical compositions containing the same

---

EP3584237B1|2020-12-09|Alpha adrenergic receptor modulators

---

KR20010049859A|2001-06-15|NEW β-CARBOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

---

BG100040A|1996-03-29|Indole derivatives as 5-ht1a and/or 5-ht2 ligands

---

KR20060113699A|2006-11-02|Substituted isoquinolinones

---

CA2520281A1|2004-10-14|Benzimidazole derivatives and their use for modulating the gabaa recept or complex

---

CA2659696A1|2008-02-07|6-1h-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents

---

JP2010528982A|2010-08-26|Quinolone compounds and pharmaceutical compositions

---

EP0517357A1|1992-12-09|Angiotensin II antagonists incorporating a substituted indole or dihydroindole

---

KR20010032435A|2001-04-25|5-|-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability

---

US20030139431A1|2003-07-24|Guanidines which are agonist/antagonist ligands for neuropeptide FF | receptors

---

JP2002326987A|2002-11-15|New triazine compound useful as sorbitol dehydrogenase inhibitor

---

US6562839B1|2003-05-13|6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both

---

US6632813B1|2003-10-14|6-subtituted-7-heteroquinoxalinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both

---

EP1914236A1|2008-04-23|Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

---

MXPA00003243A|2001-06-26|Compounds for treating and preventing diabetic complications

同族专利:

---

公开号 | 公开日

---

JP2011524383A|2011-09-01|

---

CN102159208A|2011-08-17|

---

RU2011101952A|2012-07-27|

---

MX2010014394A|2011-05-19|

---

BRPI0822462A2|2015-10-13|

---

RU2472508C2|2013-01-20|

---

US8633208B2|2014-01-21|

---

CN102159208B|2014-05-28|

---

EP2315588A1|2011-05-04|

---

PT2315588E|2013-03-25|

---

US20110118289A1|2011-05-19|

---

EP2315588B1|2012-12-19|

---

CA2728376A1|2009-12-23|

---

CA2728376C|2015-05-12|

---

ES2401679T3|2013-04-23|

---

AU2008357946B2|2013-06-20|

---

KR20110036583A|2011-04-07|

---

WO2009152868A1|2009-12-23|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US5455252A|1993-03-31|1995-10-03|Syntex Inc.|Optionally substituted 6,8-quinolines|

---

US6627647B1|2000-03-23|2003-09-30|Boehringer Ingelheim Pharmaceuticals, Inc.|Substituted 1-imidazoles and their use as anti-inflammatory agents|

---

BRPI0506909A|2004-01-16|2007-05-29|Hoffmann La Roche|1-benzyl-5piperazin-1-yl-3,4-dihydro-1h-quinazolin-2-one derivatives and their 1h-benzo thiadiazine-2,2-dioxide derivatives and 1,4 -dihydro-benzo oxazin-2-one as 5-hydroxytryptamine receptor modulators for the treatment of central nervous system disorders|

---

ITTO20040125A1|2004-03-01|2004-06-01|Rotta Research Lab|NEW HETEROCYCLIC AMIDINS INHIBITIVE THE PRODUCTION OF NITROGEN OXIDE FOR ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY|

---

RU2304029C1|2005-11-07|2007-08-10|Открытое акционерное общество "Электростальский завод тяжелого машиностроения"|Device for moving pipes|

---

ES2394971T3|2006-08-03|2013-02-07|Rottapharm S.P.A.|Derivatives of quinolines and 6-1H-imidazo-quinazoline, new potent anti-inflammatory and analgesic agents|IT1395963B1|2009-06-04|2012-11-02|Rottapharm Spa|CRYSTALLINE FORMS OF 6--2-FENYL CHINAZOLIN AND OF ITS SALTS|

---

TW201210597A|2010-06-09|2012-03-16|Gilead Sciences Inc|Inhibitors of hepatitis C virus|

---

NZ610018A|2010-11-11|2016-03-31|Bayer Ip Gmbh|Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis|

---

IN2014CN02646A|2011-09-14|2015-08-07|Samumed Llc||

---

WO2014158916A1|2013-03-14|2014-10-02|Dart Neuroscience, Llc|Substituted naphthyridine and quinoline compounds as mao inhibitors|

---

WO2015157005A1|2014-04-10|2015-10-15|E I Du Pont De Nemours And Company|Substituted tolyl fungicide mixtures|

---

US10087148B2|2014-12-05|2018-10-02|The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health|Quinazolines as biogenic amine transport modulators|

---

US9873702B2|2014-12-05|2018-01-23|Southern Research Institute|Heterocyclic compounds as biogenic amine transport modulators|

---

JP6501251B2|2015-03-12|2019-04-17|国立大学法人 長崎大学|Therapeutic agent for chronic pain|

---

CN110946865A|2015-12-10|2020-04-03|Ptc医疗公司|Methods for treating huntington's disease|

---

CN105461626B|2015-12-17|2018-05-08|浙江工业大学|Aromatic ring or condensed hetero ring connection 3,4- dihydroisoquinoliness conjugated structure compounds and its application|

---

KR20190024911A|2016-06-01|2019-03-08|사뮤메드, 엘엘씨|5-yl) pyridine-3-carboxamide was prepared by the same method as described in example 1 except that 3-1-yl) -3-methylbutanamide &lt; / RTI &gt;|

---

WO2018226622A1|2017-06-05|2018-12-13|Ptc Therapeutics, Inc.|Compounds for treating huntington's disease|

---

TW202026284A|2018-11-06|2020-07-16|美商富曼西公司|Substituted tolyl fungicides|

---

EP3735974A1|2019-05-10|2020-11-11|Rottapharm Biotech S.r.l.|Use of 2-phenyl-6-quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease|

---

WO2021104639A1|2019-11-29|2021-06-03|Rottapharm Biotech S.R.L.|Use of 2-phenyl-6- quinazoline for the prevention of abuse and of side effects of at least one opioid|

---

UY39189A|2020-05-06|2021-12-31|Fmc Corp|SUBSTITUTED TOLYL FUNGICIDES AND MIXTURES|

法律状态:
2013-10-17| FGA| Letters patent sealed or granted (standard patent)|

---

2015-01-22| PC| Assignment registered|Owner name: ROTTAPHARM BIOTECH S.R.L. Free format text: FORMER OWNER WAS: ROTTAPHARM S.P.A. |

优先权:

---

申请号 | 申请日 | 专利标题

---

PCT/EP2008/057908|WO2009152868A1|2008-06-20|2008-06-20|6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands|

---